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5. Introduction 
Sleep is one of the greatest mysteries: from birth, we spend nearly a third of our 
lives asleep. It is vital to our cognitive and physical performance, memory, health and 
well-being. Despite decades of research, we are still not sure why. The last decades saw 
a great progress in the understanding of sleep regulation. The relevance of this 
understanding is indicated by the fact that in our society sleep problems are often 
associated with a wide range of medical and psychiatric conditions, moreover, 
hypnotics are among the most frequently prescribed medications.  
According to traditional concepts, sleep is a homeostatic function, that is, a 
prolonged wakefulness is followed by rebound sleep. It is a property of the whole 
organism: the animal is awake or asleep. However, in the past few years, a new theory 
of sleep was born, namely, sleep is a local process and use-dependent. This idea 
suggests that sleep is a fundamental property of neuronal networks; the homeostatic 
regulation of sleep can occur in any part of the brain as a result of former activity [1, 2].  
5.1. The stages of sleep and wakefulness 
Falling asleep takes only a few seconds or minutes, however, in the meanwhile, 
dramatic changes are processed in the central nervous system (CNS). During the 
transition, parallel alterations can also be observed in physiological variables, such as 
breathing, arousability, closure of the eyes and muscle tone. During switching between 
sleep and wake or between different sleep stages, changes in the global pattern of 
neuronal activity can be measured by electroencephalography (EEG) [3], while the 
alterations in muscle tone can be monitored by electromyography (EMG).  
The observable extracellular field potential changes in the EEG stem from the 
synchronized electrical activity of large amount of cortical neurons. The summed 
synaptic currents of the apical dendrites of pyramidal neurons comprise the main 
contributors to EEG waves, although neuronal firing and intrinsic membrane properties 
are also involved [4].  
 
DOI: 10.14753/SE.2016.1869
11 
 
 
Figure 1. Electroencephalographic (EEG) recordings of different vigilance stages 
in human and rat. Wakefulness is characterized by desynchronized (low-amplitude 
and high-frequency) EEG in both human and rat. As sleep deepens, non rapid eye 
movement (non-REM) sleep in human can be divided into four stages, like stage 1 
(superficial sleep), stage 2 (accompanied by the appearance of sleep spindles and K-
complexes) as well as stage 3 and 4 (also called delta sleep together due to the high 
amount of high amplitude, low frequency delta waves). The EEG feature of rapid eye 
movement (REM) sleep is very similar to that in wakefulness (low-amplitude and high-
frequency) in human. In rat, non-REM sleep is also characterized by low frequency 
delta waves that increase in amplitude and decrease in frequency as sleep deepens, 
although in most cases non-REM sleep in rat is not parsed into separate stages. In the 
REM sleep of rat, strong synchronous theta activity is typical, presumably generated by 
the hippocampus. Based on Brown et al. [5].  
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Table 1. Basic EEG rhythms and the typical vigilance stages where the rhythms 
are most frequently occur in human and rat [8, 11, 12]. 
EEG rhythm Frequency range (Hz) Typical Vigilance stage 
  Human Rat 
Delta 0.5-4 non-REM III-IV slow wave sleep 
Theta 5-9 
non-REM I 
REM sleep 
wakefulness 
REM sleep 
wakefulness 
Sigma 
(spindles) 
12-14 non-REM II deep slow wave sleep 
Alpha 9-13 drowsiness 
light slow wave 
sleep 
Beta 15-30 wakefulness wakefulness 
Gamma 30< wakefulness wakefulness 
 
5.1.1. Wake 
The state of wakefulness is a complex manifestation of behaviours that are 
continually changing in response to alterations in the internal and external stimuli. This 
vigilance stage is characterized by high frequency, low voltage waves (desynchronized 
or “activated” EEG activity, see on Figure 1) with high muscular activity. These faster 
EEG rhythms with low amplitude comprise synchronized activity in small functionally 
interconnected areas. Theta rhythm, typical in wake and rapid eye movement (REM) 
sleep, appears over more widespread areas, and synchronizes faster, locally generated 
beta (15-30 Hz) and gamma (>30 Hz) rhythms (Table 1) that oscillations are considered 
to provide a temporal framework for higher-order brain functions such as conscious 
awareness, attention,  representation of spatial position and memory [6]. In rat, the 
waking state with high theta activity corresponds to the attentive and/or psychoactive 
waking comprising 23% of sleep-wake cycle, while waking without theta activity 
represents the non-attentive waking or non-motivated motor activities, called quiet or 
passive wake (PW), comprising 33% of sleep-wake cycle [7]. Theta power is 
DOI: 10.14753/SE.2016.1869
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presumably arising from the hippocampus [8]. More than one theta generator as well as 
more than one type of hippocampal theta activity has been suggested, however, the 
functional relevance of hippocampal theta activity is still not clear [6, 9].  
5.1.2. Non rapid eye movement (non-REM) sleep 
As the individual fall asleep, EEG switches to higher amplitude, slower 
frequency EEG signs (synchronized EEG activity) characteristic of non rapid eye 
movement (non-REM) sleep. Then, during non-REM sleep, the EEG slows 
progressively, until the EEG is dominated by high voltage, slow delta waves (0.5-4 Hz 
frequency, Table1). During this stage, the underlying cellular phenomenon is the slow 
oscillation (<1Hz), which contains an UP state, characterized by maintained 
depolarization and irregular neuronal firing, and a DOWN state characterized by silence 
in firing of cortical cells. Consequently, during non-REM sleep, cortical neurons show a 
firing pattern prevailed by periods of increased population activity (ON periods) 
intermitted by shorter periods of generalized silence (DOWN period), referring to the 
negative phase of EEG slow waves [10, 11]. 
Depending on the extent of synchronization, non-REM sleep can be subdivided 
into four stages in human. Stage one (non-REM I) comprises the superficial sleep, 
characterized by relative low amplitude theta frequency and vertex sharp waves. In 
stage two (non-REM II) distinctive sleep spindles (augmenting and decrementing waves 
at 12-14 Hz frequency) and K-complexes appear on the EEG. In stage three (non-REM 
III) and stage four (non-REM IV), EEG is occupied by delta waves (0.5-4 Hz) in no 
more than 50% and more than 50% of the EEG record, respectively. The deepest stages, 
like non-REM III and non-REM IV are also called slow wave sleep (SWS) or delta 
sleep [12], and recently not considered to be separate stages. Duration of a non-REM 
sleep bout typically lasts ca. 40-60 minutes in human, and about three-five minutes in 
rodents. Slow rolling eye movements and decreased tone of somatic musculature is 
typical. In rats, non-REM sleep is subdivided into two stages: light slow wave sleep 
(slow wave sleep 1, SWS1) is characterized by the occurrence of slow waves with 
increasing amplitude, while in deep slow wave sleep (slow wave sleep 2, SWS2), there 
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are spindles with progressively increasing amplitude and number interspersed by high-
amplitude, low-frequency cortical slow waves on EEG [7]. 
5.1.3. Rapid eye movement (REM) sleep 
During the switch from non-REM sleep to REM sleep, the slow waves are 
replaced by high frequency low-amplitude fast, tonically activated EEG signs. REM 
sleep is characterized by a distinct constellation of tonic and phasic features, namely, 
atony of skeletal muscles with the exception of breathing- and eye-moving muscles 
(tonic), and stereotyped bursts of saccadic eye movement, called rapid eye movements 
(phasic) observable on the electrooculogram. This sleep stage is also called paradoxical 
sleep due to the presence of an increased cortical activity while the arousal threshold is 
high. The duration of REM sleep bouts varies with species, age and heath of the 
individual lasting usually 1.5 h in human vs. 7-13 min in rodents (reviewed in [12-14].  
During REM sleep in rodent, a rhythmic theta EEG activity, generated by the 
hippocampus, is a striking feature on the EEG. In theta activity, two different subtypes 
have been observed: the Type I (4-7 Hz) theta has been demonstrated under urethane or 
ether anaesthesia and during behavioural immobility, and was abolished by atropine 
sulphate, a muscarinic antagonist, while Type II theta (7-12 Hz) has been demonstrated 
during waking associated with movements and was abolished by urethane. However, 
during REM sleep, a combination of Type I and Type II theta can be detected [9]. In 
rats, REM sleep is preceded and sometimes followed by a short stage called 
intermediate stage of sleep (IS) characterized by high-amplitude anterior cortex spindles 
and low-frequency hippocampal theta rhythm [15]. 
In humans, although low frequency (4-7 Hz) theta activity is generated mainly 
from the hippocampus, the EEG is prevailed by faster and lower voltage cortical 
frequencies. In contrast to rats, theta in humans was not detected continuously, rather in 
short (1 sec) periods, moreover, it was not correlated with the occurrence of rapid eye 
movements [16]. In humans, the IS transitional stage has been identified as part of the 
non-REM II sleep [12].   
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5.2. The role of brain structures in the regulation of sleep-wake cycle 
The regulation of sleep-wake cycle is based on two independent processes: the 
circadian rhythm and the homeostatic drive [17]. In mammals, the circadian rhythmicity 
of vigilance is determined by the function of the hypothalamic suprachiasmatic nucleus 
(SCN), a key pacemaker that translates the light-dark information from the retina into 
transcriptional and translational feedback loops of clock genes, and regulates 
behavioural responses with a roughly 24 h period [18]. In homeostatic sleep regulation, 
the length and depth of sleep is driven by sleep-promoting molecules, such as 
adenosine, which may accumulate extracellularly as a by-product of cellular 
metabolism. In other words, if someone is sleep-deprived for a period of time, he/she 
will have an increase in the subsequent sleep-time to compensate deprivation [2, 14, 
19].  
Regarding the transition between different vigilance stages, a mutually 
inhibitory relationship between sleep- and wake-promoting systems in the brain 
generates a flip-flop switch that is presumed to allow a sharp transition between sleep 
and wakefulness  [14]. However, a similar switch is thought to regulate the transition 
between non-REM and REM sleep through the mutually antagonistic relationship of 
REM-on and REM-off neuronal populations [20] (Figure 2). In the brain, the mutual 
inhibition is between large populations of neurons, which may also respond to other 
stimuli at the same time, consequently the transition will take seconds to minutes, 
depending on the species, and the developing behavioural state is most likely the result 
of the summed activity across all neurons. However, this switch ensures stable sleep and 
wake, thus, lesion of a single component of the sleep-wake circuitry can destabilize the 
sleep switches, as shown by the example of narcolepsy [14, 21].  
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Figure 2. “Flip-flop” model of wake - sleep and REM - non-REM sleep switch, and 
how this cascade is stabilized by orexin/hypocretin (Hcrt) neurons (based on Saper 
et al. 2010 [18]). In the regulation of vigilance, the “switch” between sleep and 
wakefulness (at the upper left) is established by the mutually inhibitory relationship of 
sleep promoting structures [ventrolateral preoptic area (VLPO), median preoptic 
nucleus (MnPO)] and wake-promoting structures [dorsal raphe nucleus (DRN), median 
raphe nucleus (MRN), locus coeruleus (LC), tuberomamillary nucleus (TMN), 
parabrachial nucleus (PB) and the adjacent precoeruleus area (PC) and the ventral 
periaqueductal gray matter (vPAG)]. There is an also mutually inhibitory relationship 
between structures having REM-on- [laterodorsal tegmentum (LDT), pedunculopontine 
tegmentum (PPT), sublaterodorsal tegmentum (SLD), and PB/PC] and REM-off- 
[ventrolateral periaqueductal gray matter (vlPAG) and LPT] characteristic (at the lower 
right). The monoaminergic arousal neurons inhibit the VLPO during wakefulness, but 
also prevent the generation of REM sleep by inhibiting the REM-on neurons and 
exciting the REM-off neurons. Thus, the wake-REM sleep transition is practically 
impossible for normal individuals. In the stabilization of the “flip-flop switch” between 
non-REM and REM sleep as well as wakefulness, the orexin/hypocretin (Hcrt)- and 
melanin-concentrating hormone (MCH)-expressing neuron populations, intermingled in 
the hypothalamus, are considered to have a key role.  
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5.2.1. Brainstem 
The importance of brainstem in the regulation of brain state and muscle tone is 
crucial: its extensive damage can cause coma, a state of unconsciousness and 
unresponsiveness. In the maintenance of wakefulness, two critical pathways originate 
from the brainstem (i) the ascending reticular activating system (ARAS) projecting to 
the thalamus, hypothalamus, basal forebrain (BF), and neocortex being important for 
cortical activation, and (ii) the descending pathway to the spinal cord being crucial for 
the maintenance of muscle tone [22] (Figure 3).  
The ARAS comprises serotonergic neurons mostly from the dorsal and median 
raphe nuclei (DRN and MRN, respectively), noradrenergic neurons from the locus 
coeruleus (LC) and dopaminergic neurons from the area adjacent to the DRN, as well as 
cholinergic neurons from the pedunculopontine tegmental (PPT) and laterodorsal 
tegmental (LDT) nuclei. The ARAS also includes histaminergic neurons from the 
tuberomamillary nucleus (TMN), although this structure is localized in the posterior 
hypothalamus (PH, see later in section 5.2.4.2). The monoaminergic neurons, including 
DRN, LC and TMN neurons, show their highest firing rate at wakefulness, low rates 
during non-REM sleep while they nearly silent during REM sleep [23-25]. The relative 
small number of noradrenergic neurons in the LC (ca. 1500 in rat) innervates almost the 
entire CNS [26] and possibly has a role in generating arousal during conditions that 
needs high level of attention or activation of the sympathetic nervous system [23]. The 
importance of this structure is shown by the finding that optogenic stimulation of the 
noradrenergic neurons can lead to immediate awakening [27]. Moreover, noradrenergic 
release in the cortex is essential for the EEG desynchronization [28] (Figure 3).  
The serotonergic neurons of the DRN and MRN project widely to the cortex and 
subcortical areas, including the BF, thalamus, hypothalamus and the preoptic area 
(POA). Besides its involvement in the regulation of vigilance, serotonin (5-
hydroxytryptamine, 5-HT) has been shown to regulate many other aspects of behaviour 
such as appetite, mood, aggression and anxiety.  Early studies suggested that 5-HT 
might promote non-REM sleep and possibly REM sleep, however, more recent studies 
have indicated that serotonin generally induces wakefulness and suppresses REM sleep 
(reviewed in [29]). In agreement with this role, agonists of the 5-HT1A, 5-HT1B, 5-HT2, 
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or 5-HT3 receptors elevate wakefulness [30-33]. Of clinical relevance, increased 
extracellular 5-HT concentration can be elicited by the application of selective serotonin 
reuptake inhibitor (SSRI) antidepressants, like fluoxetine or escitalopram, that agents 
had been shown to increase wakefulness while suppress REM sleep in both humans and 
rodents [34-36].   
The LDT/PPT cholinergic neurons, comprising one of the two major cholinergic 
cell populations, send extensive projections to subcortical regions including the 
thalamus, lateral hypothalamus and BF [37]. In contrast to the monoaminergic 
components of the ARAS, cholinergic neurons show high firing rate during both 
wakefulness and REM sleep [38]. Thus, the cholinergic system seems to be linked to 
cortical EEG desynchronization typical during wakefulness and REM sleep, but not 
necessarily to behavioural arousal. The impact of the PPT is suggested by the fact that 
lesion of the cholinergic neurons of PPT causes significant reduction in the amount of 
REM sleep [39].  
Also glutamatergic neurons from the rostral pons, localizing in the parabrachial 
nucleus and the adjacent precoeruleus area, have been postulated to participate in the 
maintenance of wakefulness (Figure 3). These neurons have been demonstrated to send 
projections to the cerebral cortex, BF and the lateral hypothalamus. Although the firing 
pattern of these neurons have not been investigated yet, studies with the early gene 
product Fos (see later in section 5.3) have found mostly wake- and REM sleep -active 
neurons in these regions [14, 20]. 
5.2.2. Basal forebrain 
The cholinergic neurons of the BF give the primary source of cholinergic input 
to the cortex and the hippocampus, and in line with this, have a role in the cortical 
desynchronization. These cholinergic neurons, similarly to the LDT/PPT group, show 
their highest firing rate during wake and REM sleep, while in non-REM sleep their 
neuronal activity is minimal [40-42]. The BF also contains a large group of neurons that 
release the inhibitory neurotransmitter γ-aminobutyric acid (GABA), which neurons 
may activate the cortex by decreasing the activity of inhibitory cortical interneurons 
[43] (Figure 3). On the contrary, recent data suggest a dual function of BF in the 
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modulation of cortical activation and behavioural state, namely, populations of GABA-
ergic BF neurons have been shown to facilitate cortical activation by modulating 
gamma or theta activity, while other subgroups decrease cortical activation by 
modulating irregular slow oscillations that normally occur during SWS [44].  
 
 
Figure 3. Schematic drawing illustrating the key circuits involved in the regulation 
of sleep and wakefulness in rat brain. Red and blue arrows indicate the major 
pathways of cortical desynchronization and synchronization, respectively. Black arrows 
demonstrate pathways that mediate both synchronization and desynchronization. 
Possible pathways of desynchronization and synchronization are shown by light red and 
light blue arrows, respectively. Different cell types are illustrated by coloured circles in 
each brain areas. Abbreviations: GABA: gamma-aminobutyric acid, MCH: melanin-
concentrating hormone (Based on Lee et al., 2012) [45].  
 
5.2.3. Thalamus and cortex 
Thalamus comprises the gateway of sensory input to the cortex and can directly 
influence state of the cortex. The highly interconnected thalamocortical, thalamic 
reticular and cortical neurons comprise the thalamocortical loop which has a crucial role 
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in setting the global brain state and in regulating the flow of sensory information [46, 
47]. Thalamic neurons show distinct modes of firing in different vigilance stages 
demonstrating tonic spiking in alertness and rhythmic bursting in drowsiness or non-
REM sleep [48]. Delta oscillation and spindles are generated in sleep or drowsiness by 
the intrinsic properties of the thalamocortical and thalamic reticular neurons and 
through their synaptic interactions [48]. Thalamus receives strong input from the ARAS 
and the BF [37, 49] comprising the major pathway through which the neuromodulatory 
system can influence cortical function [45] (Figure 3).  
Cortical neurons can also influence the global state of the brain. In non-REM 
sleep, slow oscillations originate in the cortex [10], and cortico-cortical connections are 
sufficient for the synchronization of the oscillations across different brain areas [50]. 
Notably, in anesthetized rat, high-frequency burst firing of a single cortical neuron has 
been found to be sufficient to induce transition in the global brain state, either from a 
synchronized to desynchronized state or vica versa [51]. Cortical neurons are highly 
interconnected with thalamic neurons and can also exert strong influences on the global 
brain state. Neurons from the prefrontal cortex provide strong descending inputs to the 
neuromodulatory circuits in the BF [52]and the brainstem [45, 53] 
5.2.4. Hypothalamus 
The role of hypothalamus in the regulation sleep and wakefulness was first 
hypothesized during the epidemic encephalitis letargica around the time of the First 
World War by Constantin von Economo, who reported lesions in the preoptic region 
around the rostral end of the third ventricle in patients suffering from profound 
insomnia. A smaller part of patients suffering from encephalitis letargica showed 
opposite symptoms: they became insomniac and slept only for a few hours each day 
despite being extremely tired.  These patients had lesions in the anterior hypothalamus 
and basal ganglia [54]. Recently, the crucial role of the hypothalamus in the regulation 
of sleep and wakefulness has been rediscovered, shifting the focus away from the 
thalamocortical system and the brainstem. As a key integrator centre of the brain, the 
hypothalamus expresses several neuropeptides and transmitters to synchronize the 
regulation of basic physiological functions of the body, like food intake, temperature, 
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energy homeostasis, stress response and reproduction with the circadian pacemaker of 
the body as well as the sleep-wake cycle [55]. 
5.2.4.1. The preoptic area 
In the POA, two neuronal populations have been identified as sleep-promoting 
structures: the ventrolateral preoptic area (VLPO) and the median preoptic nucleus 
(MnPO) [56, 57]. The key property of VLPO neurons, that they have reciprocal 
innervations with several components of the ARAS, including DRN and adjacent 
ventral periaqueductal grey matter (vPAG), TMN, LC and parabrachial nucleus [20, 
58]. The dense core of the VLPO innervates the histaminergic TMN, and includes 
GABA- and galanin neuropeptide-containing neurons that show their highest firing rate 
during non-REM sleep. However, a more diffuse population of VLPO, the extended 
VLPO, innervates DRN and LC [59, 60]. Cell-specific lesions of the VLPO core 
correlated most closely with non-REM sleep decrease, while the cell loss of the 
extended VLPO correlated rather with the decline of REM sleep [60]. The major input 
of VLPO is provided by the MnPO that contains mostly sleep-active GABAergic 
neurons that do not contain galanin [58, 61]. In contrast to VLPO, the neurons of which 
increase firing rate during sleep just from sleep onset, neurons of MnPO often fire in 
advance of sleep, suggesting a role in accumulating sleep pressure [61].  The mutual 
inhibition between sleep-active neurons of VLPO-MnPO and the ARAS-lateral 
hypothalamus led to the proposal of a flip-flop model (see in chapter 5.2, Figure 2) for 
sleep-wake switches [14].  
5.2.4.2. The posterior hypothalamus 
The involvement of PH was postulated by the early experiments of Nauta [62] 
who demonstrated that large posterior hypothalamic lesions led to a continuous sleep-
like state. Further research identified two arousal-related neuronal populations in the 
PH: a histaminergic cell group in the TMN [63] and an orexin/hypoctretin 
neuropeptide-containing cell population in the perifornical hypothalamic area (PFH, 
perifornical area and lateral hypothalamus).  
Similarly to the monoaminergic components of ARAS (see before), 
histaminergic TMN neutrons show their maximal firing rates in wakefulness, though 
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silent during non-REM sleep [63, 64]. Many TMN neurons discharge robustly also 
during REM sleep suggesting a possibly stronger correlation with EEG desynchrony 
than with wakefulness itself. In line with this, axons from TMN neurons target 
predominantly the lateral hypothalamus, BF and the cerebral cortex, where they 
terminate, particularly in the prefrontal cortex [65]. Histaminergic TMN neurons, 
influence sleep-wake state through reciprocal interactions with sleep promoting systems 
in the anterior hypothalamus [66], BF and brainstem arousal systems.  
5.2.4.3. The lateral hypothalamic area 
The lateral hypothalamic area (LH), being an important integrator region of the 
brain, has been implicated in a wide variety of functions, such as energy homeostasis, 
regulation of motor activity as well as motivation and reward [67]. A growing body of 
evidence sustains the role of this area with the PH as a key centre in the regulation of 
vigilance [68-70]. The impact of LH in the regulation of sleep-wake cycle is shown by 
the fact that reversible inactivation of this area, using muscimol a GABAA agonist, 
completely abolishes REM sleep [71]. Moreover, neurons showing REM-specific firing 
pattern have been recorded from this area.  
In the lateral hypothalamus and the adjacent perifornical area (PFA), just dorsal 
and rostral to the TMN histaminergic cell population, another arousal-related neuronal 
system has been identified, namely the orexin/hypocretin (Hcrt) neuropeptide-producing 
neurons. Hcrt neurons are essentials for the maintenance of waking, showing their 
highest firing rate during wakefulness, decreasing their activity in non-REM sleep, and 
being almost silent in REM sleep [72]. Partly intermingled (although not co-expressing) 
with the Hcrt neurons in the LH and PFA, the melanin-concentrating hormone (MCH)-
containing neurons are localized [73, 74] playing an opposite role in the regulation of 
sleep-wake cycle promoting sleep, particularly REM sleep [72, 75-77]. For the 
connection between MCH and Hcrt neurons and their innervations, see Figure 4.  
Notably, MCH and Hcrt neurons send parallel projections innervating almost the entire 
CNS, including the cortex, amygdala, hippocampus, nucleus accumbens, thalamus, 
hypothalamus, ventral tegmental area (VTA), LDT/PPT nuclei, raphe nuclei and LC 
suggesting common, integrative roles in the central regulation of vigilance, food intake 
and energy expenditure [70, 73, 78-80]. All MCH-containing neurons express a relative 
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novel neuropeptide, the nesfatin/NUCB2, identified in 2006 [81], however, the role of 
this peptide in the regulation of sleep-wake cycle had not been investigated until the 
beginning of our experiment.   
 
Figure 4. Schematic illustration of the connection between the orexin/hypocretin 
(Hcrt) and the melanin-concentrating hormone (MCH)-containing neurons and 
their innervations. MCH neurons contain gamma-aminobutyric acid (GABA), 
cocaine-amphetamine-regulated transcript (CART), nesfatin and endocannabinoids, 
while Hcrt neurons express neuronal activity regulated pentraxin (Narp), dynorphyn and 
glutamate. In the interaction between MCH and Hcrt neurons, MCH neurons inhibit 
Hcrt neurons, while the influence of Hcrt neurons on MCH neurons can be excitatory or 
inhibitory. Abbreviations: noradrenaline (NA), serotonin (5-HT), acetylcholine (Ach), 
dopamine (DA), neuropeptide Y (NPY), corticotropin releasing factor (CRF). Red and 
green arrows show inhibitory or excitatory innervations, respectively, while yellow 
arrow means that both inhibitory and excitatory connection can be present. Based on 
Konadhohe et al., 2014 [82].  
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5.2.4.3.1. The hypocretins /orexins 
The orexin A and B, also called hypocretin-1 and 2 (Hcrt) have been discovered 
by two groups independently [83, 84]. The term hypocretin (i.e. hypothalamus-specific 
secretin-like peptide) comes from the fact that Hcrt-positive neuronal somata have been 
reported only in the PFH [83], while the term orexin emphasizes their obvious role in 
the appetite regulation [84]. The importance of the Hcrt system in the sleep-wake 
regulation was suggested by the discovery of decreased expression of Hcrt peptides and 
Hcrt receptors in the background of narcolepsy both in humans and dogs [85, 86]. 
Additionally, narcolepsy-like phenotype has been reported in Hcrt knock-out mice [87] 
and in rats with specific Hcrt-directed neurotoxic lesions [88]. Narcolepsy is 
characterized by the inability to sustain wakefulness, frequent state transitions and 
inappropriate intrusions of REM sleep-related phenomena (i.e. motor atonia) during 
wakefulness, suggesting the specific function of Hcrt neurons in ensuring the stability 
and maintenance of non-REM and REM sleep as well as wake stages [14]. Additionally, 
central administration of Hcrt has been shown to elevate wake and decrease non-REM 
and REM sleep [89], and blockade on Hcrt receptors promotes both non-REM and 
REM sleep at the expense of wakefulness [90]. This relative small neuron population 
(ca. 6700 neurons in the rat brain) [76] gives excitatory projections to all other arousal- 
and wake-related cell groups, including the cholinergic neurons in the BF, the 
histaminergic cells in the TMN as well as cholinergic and aminergic cells in the 
brainstem [91], suggesting the wake-executive property of Hcrt neurons in the 
regulation of vigilance [92]. Hcrt 1 and 2 are neuro-excitatory peptides, and binding to 
specific receptors (Hcrt-1R and Hcrt-2R) evoke excitatory post-synaptic effects when 
released from the glutamatergic Hcrt-neurons [78, 93]. In addition, nearly all Hcrt 
neurons also contain the neuropeptide dynorphin [94].  
5.2.4.3.2. The melanin-concentrating hormone (MCH) 
MCH is a 19-amino acid peptide, with a conservative structure that is identical 
in all mammals examined to date, including rabbits, rats, mice, and humans [95].The 
MCH-expressing neuronal population (ca. 10,000-12,000 in the rat brain), localizing in 
the zona incerta/subzona incerta (ZI), LH and the PFA [73]. A small number of MCH-
containing neurons have also been demonstrated in the pontine reticular formation and 
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the olfactory tubercle in rat, as well as in the LDT and POA of female and lactating rats, 
respectively [73, 96, 97]. MCH-containing fibres are in close relationship with Hcrt 
neurons and vice versa, moreover, hypocretinergic receptors are present on MCH 
neurons, suggesting reciprocal synaptic contacts between MCH and Hcrt neurons as 
well as an important functional interaction between the two systems [98, 99]. Earlier 
studies have reported that Hcrt neurons increase MCH mRNA expression, directly 
exciting MCH neurons as well as elevating glutamate release onto them [75, 100]. 
However, recent optogenic data show that firing of Hcrt neurons exerts inhibitory effect 
on most MCH neurons via GABAA receptors, while bath-applied Hcrt caused excitation 
only in a minority of MCH neurons (Figure 4), providing evidence for a GABAergic 
microcircuit that, by a potential feed-forward loop, may stabilize the switch between 
sleep and wakefulness [101]. On the contrary, MCH neurons exert a unique inhibitory 
effect on hypocretinergic signaling as a way to fine-tune the output of these neurons 
[102] (Figure 4). To date, two receptor of MCH have been identified, the MCHR1 and 
MCHR2 that show 38% sequence homology [103, 104]. While binding of MCH to 
MCHR1 activates diverse intracellular signaling pathways by coupling to Gi, Gq and G0 
proteins, MCHR2 is known to couple only to Gq [104, 105]. Similarly to centrally 
administered Hcrt, intracerebroventricularly (icv)-injected MCH has been demonstrated 
to stimulate feeding [84, 106]. Targeted deletion of either the MCH gene or melanin-
concentrating hormone MCH1 receptor in mice led to hypophagic lean mice [107], 
while overexpression of the prepro-MCH resulted in obese mice [108]. Moreover, non-
peptide MCHR1 antagonist has been found to abolish the MCH-induced feeding 
behaviour and diminished body weight [109].  
Beyond the involvement of MCH in food intake, additional physiological 
evidence suggests its role in the regulation of sleep and wakefulness (reviewed in [110, 
111]. While Hcrt neurons have a critical role in the maintenance of wakefulness, MCH 
neurons increase their firing rate during slow wave sleep (SWS) and show their 
maximal firing rate in REM sleep [72]. The implication of MCH in sleep-regulation is 
strengthened by the fact that centrally administered MCH elevated the time spent in 
REM sleep (~200%), and to a lesser degree, the amount of SWS [112], moreover, 
MCHR1 antagonists dose-dependently decreased SWS2, IS as well as REM sleep, 
while  active and passive wake have been found to increase [113]. In addition, 
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optogenic activation of MCH neurons promotes REM sleep [114]. Interestingly, 
regarding the function of MCH-containing neurons, the action of MCH neuropeptide 
does not seem to be as important as GABA release from these neurons, causing 
inhibitory post-synaptic effect [70, 114].  
In accordance with its role in promoting sleep, activity of MCH-containing 
neurons is regulated by components of the wake-promoting system. Namely, MCHergic 
neurons are hyperpolarized by noradrenaline (NA), serotonin, acetylcholine [100], while 
dopamine reduces the excitability of MCH-containing neurons by decreasing the 
membrane resistance without modifying the resting potential [115] (Figure 4). 
Cannabinoids, being sleep-promoting neuromodulators, increase the firing rate of 
MCH-containing neurons by decreasing the activity of nearby GABAergic neurons via 
CB1 receptors [116].  
In the MCH-containing cells, MCH is generated by the cleavage of the prepro-
MCH precursor, which contains other neuropeptides besides MCH, such as 
neuropeptide EI (NEI) and neuropeptide GE (NGE) [73]. In addition to prepro-MCH-
derived neuropeptides, other neurotransmitter and neuromodulators have been 
demonstrated to co-localize with MCH, like the anorexinergic cocaine- and 
amphetamine-regulated transcript (CART). In the ZI and the lateral hypothalamus of 
rat, 95% and 70% of the MCH-containing neurons co-express CART, respectively 
[117]. The MCH population, based on the CART positivity, can be separated 
functionally into two MCH subpopulations, namely, (i) the CART co-localizing MCH 
neurons sending ascending projections toward the septum and hippocampus, whereas 
(ii) the non-CART MCHergic neurons send descending projections toward the 
brainstem and spinal cord [118].  
Considering physiological functions, MCH possesses an integrative role in 
energy conservation by decreasing metabolism and promoting sleep as well as food 
intake. In line with this, MCH reduces heart rate, temperature and metabolic rate by 
central actions, namely, it elevates the parasympathetic/sympathetic rate and diminishes 
the release of thyroid hormones [95]. The MCHergic system is thought to play a crucial 
role in special cases, when the energy conservation is indispensable. One example is 
hibernation, when the metabolism of the body decreases to 1-2% of the basal level. 
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 Notably, the entrance to this stage is via SWS [119]. Another example is 
lactation, when activity of the MCHergic system is suggested to be high [111]. In 
lactation period, MCH expression in the medial preoptic area, a crucial region in the 
maternal behaviour, is very high [97]. Interestingly, milk ejection is preceded by EEG 
synchronization, and lactation period is accompanied by somnolence in rats [120]. In 
lactating humans also the increase of SWS has been reported [121].  
According to preclinical studies, dysfunction of the MCH-system can be 
associated with many pathophysiological conditions. Shimida et al. [107] have reported 
that prepro-MCH knockout mice are anorectic and lean, while over-expression of MCH 
leads to obesity [108]. Wermter at al. have found association between single-nucleotide 
polymorphism in the MCHR1 gene and obesity investigating German children and 
adolescence [122]. Consequently, antagonists of the MCHR1 could be a potential 
therapeutic target in the treatment of obesity [123]. In addition, the involvement of 
MCH has also been suggested in the inflammatory processes of the intestine [124].  
Regarding neuropsychiatric disorders, MCH evokes predominantly depression-
like effect when injected into the DRN, while immunoneutralization of MCH had an 
antidepressive effect [125]. Similarly, antagonists on the MCHR1 evoked antidepressant 
effects in several model of depression and anxiety [109]. In line with its pro-depressive 
effect, MCH promotes the occurrence of REM sleep in animal studies [112], which 
sleep alteration is considered a characteristic feature in major depression disorder [35]. 
Taken together the above mentioned facts, MCHR1 antagonist can be potential drug 
targets in the treatment of depression and anxiety in the future.  
Recent results has also associated MCH with the pathomechanism of narcolepsy. 
Bergman et al. have identified an autoantibody in the sera of a group of narcoleptic 
patients that showed a selective binding to MCH/proopiomelanocortin (POMC) in the 
hypothalamus, and this autoantibody, when injected centrally, altered the sleep pattern 
of rats similarly to the effect of MCHR1 antagonists [21].  
5.2.4.3.3. The nesfatin-1/NUCB2 
The 82-amino acid nesfatin-1 protein is the posttranslational product from the 
cleavage of the prohormone NEFA (for DNA binding/EF-hand/acidic protein) 
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/nucleobinding-2 (NUCB2). The structure of nesfatin-1/NUCB2 (nesfatin), showing 
85% homology, is highly conserved among mammalian species. The NUCB2 
polypeptide, composed of 396 amino acids, is preceded by a 24-amino acid signal 
peptide, which protein consists of an N-terminal signal peptide, a Leu/Ile rich region, a 
DNA-binding domain, a nuclear targeting signal, two Ca
2+
-EF-hand motifs and a 
leucine zipper domain [126].  The suspected major fragments of processing are the 
nesfatin-1 (spanning residues 1-82), nesfatin-2 (residues 85-163) and nesfatin-3 
(residues 166-369) [81]. Nesfatin-1 molecule consists of three domains: the N-terminal 
(N23), the middle part (M30) and the C-terminal (C29). Among these parts, the M30 
active core seems to play the key role in physiological effects of nesfatin [81].  
Nesfatin has been suggested to influence cross-binding of its presumptive 
receptor with various types of G protein, initially activating Gi, followed by the 
activation of Gs protein, although its receptor(s) has/have not been cloned yet [127]. 
Nesfatin has a wide distribution in the CNS, such as in the forebrain, the 
hindbrain, the brainstem and the spinal cord. Using immunohistochemistry (IHC), the 
largest nesfatin- immunoreactive (IR) population has been localized in the PFA and the 
lateral hypothalamus including the dorsolateral hypothalamus (DLH) and the ZI. In the 
hypothalamus, nesfatin-containing neurons can also be detected in the arcuate, 
paraventricular (PVN) and supraoptic nuclei (SON). The anterior and intermediate 
pituitary host a substantial number of nesfatin-positive neurons as well. Regarding areas 
outside the hypothalamus, nesfatin-IR neurons have been detected in the piriform and 
insular cortex, endopiriform and central amygdaloid nuclei, lateral septum, bed nucleus 
of the stria terminalis, medial preoptic area, raphe and ambiguous nuclei, ventrolateral 
medulla and gigantocellular reticular nucleus as well as the Purkinje cells in the 
cerebellum. Nesfatin-IR neurons have also been detected in the spinal cord in both 
sympathetic and parasympathetic preganglional neuronal groups, originating from 
thoracic, lumbar and sacral segments [126, 128-131].  
In the LH, nesfatin is co-localized with several neuropeptides, like POMC, 
corticotrophin-releasing hormone (CRH), CART, neuropeptide Y (NPY), oxytocin and 
vasopressin [131, 132], as well as with neurotransmitters, like serotonin and NA. In the 
DLH and ZI, all MCH-containing neurons co-express nesfatin, and only a small portion 
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of nesfatin-IR neurons are MCH-negative [128]. In hypothalamic nuclei, nesfatin is also 
co-localized with a most recently identified peptide, the phoenixin (PNX) that shows a 
similar distribution like nesfatin [133]. Most of the above mentioned neuropeptides 
have also been involved in the regulation sleep-wake cycle, besides other roles, like 
stress-response or feeding, suggesting their integrative role in basic physiological 
functions.  
Initial functional and neuroanatomical studies have supported the role of nesfatin 
as a satiety molecule. Central administration of the peptide has been shown to depress 
nocturnal food intake in rats in a dose-dependent manner. However, neither nesfatin-2 
nor nesfatin-3 possesses this anorectic effect. Additionally, chronic icv infusion of 
nesfatin has been demonstrated to reduce body weight gain and the amount of white 
adipose tissue in rats [81, 130]. Beyond regulating food consumption, accumulating 
evidence proves that nesfatin plays an important role in the regulation of other 
physiological functions, like body temperature [134], blood pressure via the 
hypothalamus melanocortin 3/4 receptor (reviewed in [135]), operation of the 
reproductive axis [136], moreover, nesfatin has an anti-hyperglycaemic effect by 
regulating hepatic glucose production [137]. Nesfatin has also been involved in anxiety- 
and stress-related responses [138-141]. Acute 30-min restrain stress, involving 
physiological and physical stress components, has been shown to induce the activation 
of nesfatin-containing neurons in the PVN, SON, LC, ventrolateral medulla, NTS, DRN 
and rostral Raphe pallidus, although this relatively strong neuronal activation was not 
accompanied by an increased nesfatin level in the plasma [142, 143]. Another study has 
reported that icv administration of nesfatin-1 elevated the circulating level of 
adrenocorticotropin (ACTH) and corticosterone, indispensable elements of the 
hypothalamus-pituitary adrenal axis (HPA), suggesting the HPA-stimulating effect of 
nesfatin, moreover, bilateral adrenalectomy increase the expression of NUCB2 mRNA 
in the PVN [139] [143]. These data postulate nesfatin as a potential new player in the 
stress adaptation response, and thus, suggest the role of nesfatin in the pathology of 
stress-associated mood disorders, like anxiety and depression [141].  
Anxiety is obviously a stress-related disorder, however, it has a profound effect 
on feeding behaviour as well [144]. The first evidence for the involvement of nesfatin in 
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anxiety has been demonstrated by Merali et al., indicating that icv administered nesfatin 
dose-dependently enhances anxiety- and fear-related behaviours in rat, as shown by 
different behavioural tests assessing the innate anxiety response and the conditioned 
fear response, through the activation of the melanocortin pathways [138] possibly 
inhibiting GABAergic neurons or hyperpolarizing NPY neurons in the nucleus arcuatus 
[145].  
Nesfatin has also been associated with depression, that is, similarly to anxiety, 
also a common stress-related pathophysiology in humans with two-times higher 
incidence in women [146]. Ari et al. have reported a two-fold increase in plasma 
concentration of nesfatin in patients with major depressive disorder without any 
difference between genders [147]. In agreement with this, almost two-times higher 
NUCB2 mRNA level has been found in post mortem samples of rostroventral midbrain 
punches including the Edinger-Westphal nucleus of depressed suicide victims, 
compared to controls. In contrast to men, in female suicide victims, the expression was 
three-times lower, compared to female controls. Noteworthy, that basal expression of 
NUCB2 mRNA did not differ between males and females [148]. These finding suggest 
that nesfatin may play a role in the sex-specific pathobiology of depression. However, 
due to the limited number of studies, the causality has not been established yet [141]. 
 From a clinical point of view, nesfatin can be a potential drug target in the 
treatment of depression or anxiety as well as metabolic disorders and obesity, 
particularly for patients taking antidepressive and antipsychotic medications, as 
resistance to leptin or some adipokines in these patients are common [149]. Another 
promising clinical application of nesfatin can be its use as a biomarker in epilepsy, since 
positive correlation has been found between nesfatin level in body fluids (plasma, 
saliva) and the course of epilepsy [150].   
5.3. Fos expression as an indicator of neuronal activity 
In neurobiology, Fos (also called c-Fos) protein, the product of one of the 
immediate early genes (IEGs) c-fos, is a widely used, reliable functional anatomical 
marker to visualize neuronal activity in the CNS. The expression of c-fos induces Fos 
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protein synthesis that returns to the nucleus after synthesis and acts as a transcription 
factor to regulate the expression of other genes. Synthesis of the Fos protein is induced 
in response to several extracellular signals such as growth factors, neurotransmitters 
(with the exception of GABA and gylcine), neuromodulators, drugs, thermal, visual and 
somatosensory stimuli [151, 152], while its level is low in the brain under basal 
conditions. Thus, the expression of c-fos (mRNA or the Fos protein) can be visualized 
by combining with various markers, including neuropeptides, proteins or retrograde 
tracers, etc. The expression of c-fos mRNA is induced in 20 minutes after stimulus, 
whereas the accumulation of Fos protein requires up to a 90-minute period [151, 153]. 
High levels of Fos protein are generally observed for hours and then decline 
progressively [154]. For instance, Fos protein reaches its peak level in the SCN in one-
two hours after a five-minute light pulse and disappears within six hours [155]. Fos-
induction is more effective when the stimulus is novel or when applied following a 
period of deprivation [151].   
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6. Objectives  
Hypothalamus, the key integrator area of several physiological functions in the 
brain, has a crucial role also in the regulation of sleep. Thus, the role of neuron 
populations expressing different neuropeptides in the regulation of sleep-wake cycle is 
an intensively investigated area with countless new questions.  
Several data support the role of MCH in the regulation of sleep, besides other 
important physiological functions [99, 110, 112, 118].  Former data from our laboratory 
showed a positive correlation between the time spent in REM sleep during ‘REM sleep 
rebound’ and the activation of MCH-containing neurons [77], although it was not 
investigated how the MCH populations of different hypothalamic structures respond to 
‘REM sleep rebound’.  It was also pending if an increased serotonergic-tone, known to 
suppress REM sleep even during the ‘REM sleep rebound’ is able to modify the 
activation of MCH neuron populations.  
To examine this question, we applied a selective REM sleep deprivation 
followed by ‘REM sleep rebound’ to provoke increased neuronal activation of 
hypothalamic structures possibly involved in the regulation of REM sleep, parallel with 
the robust elevation in REM sleep. Neuromorphological examination of the brains 
enabled us to visualize the altered activation of different neuron populations as a result 
of ‘REM sleep rebound’. 
All hypothalamic/thalamic MCH neurons co-express nesfatin-1/NUCB2 
(nesfatin), the neuropeptide that has an opposite effect on many physiological functions, 
however, a relative smaller population of hypothalamic nesfatin-positive neurons does 
not contain MCH. As no literature data was available about the role of nesfatin in the 
regulation of vigilance, we aimed to investigate this issue using immunohistochemistry 
and electrophysiology.  
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Based on the above mentioned aspects, our aims were the followings:  
1. We intended to investigate if ‘REM sleep rebound’ causes any difference in the 
activation of MCH neurons of different hypothalamic/thalamic nuclei, such as ZI, LH 
and PFA. 
2. Considering that escitalopram, the extracellular serotonin level-increasing 
antidepressant, suppresses REM sleep, even during ‘REM sleep rebound’, how 
escitalopram treatment influences the neuronal activation of MCH-neuron population 
during ‘REM sleep rebound’ in the investigated hypothalamic/thalamic nuclei?  
3. How the activation of the hypothalamic/thalamic nesfatin-positive neuron population 
is influenced by REM sleep deprivation and the following ‘REM sleep rebound’? Is 
there any difference between the activation of MCH-positive and -negative nesfatin– 
neuron populations in different hypothalamic/thalamic nuclei? 
4. How the exogenously (icv) administered nesfatin-1 peptide injected in the passive 
phase affects the architecture of sleep-wake cycle?  
5. Does the icv injected nesfatin-1 alter the quantitative EEG spectra of different 
vigilance stages in passive phase?  
6. Is there any similarity in the EEG spectral effect of icv-injected nesfatin-1 vs. 2 or 10 
mg/kg escitalopram, suggesting a possible serotonergic component in the action of 
nesfatin-1 on vigilance? 
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7. Materials and methods 
7.1. Housing of the animals 
Experiments and housing conditions were performed according to the 
international regulations [European Communities Council Directive of 24 November 
1986 (86/609/EEC)] and the “Principles of Laboratory Animal Care” (National Institute 
of Health). All experiments were approved by the National Scientific Ethical Committee 
on Animal Experimentation, and permitted by the government (Food Chain Safety and 
Animal Health Directorate of the Central Agricultural Office, Permit Number: 
22.1/1375/7/2010).  
Male Wistar rats (from the Semmelweis University, Animal Facility, Budapest, 
Hungary) weighing 300–350 g were used. Animals were kept under controlled 
environmental conditions, with light-dark cycle of 12:12 h (10:00 A.M.-10:00 P.M, 
daylight type fluorescent tubes, 18 W, approximately 300 lx) at room temperature 
(21±1°C), and had free access to standard rodent chow and tap water. Animals were 
habituated to the conditions in the experimental room at least for two weeks. All efforts 
were made to minimize pain and suffering during the experiments. 
7.2. Neuromorphological studies: Experiment 1 and 2 
7.2.1. REM sleep deprivation (flower pot) method  
For REM sleep deprivation in Experiment 1 and 2, we used the classic flower 
pot (platform on water) method set up earlier in our laboratory [112, 156, 157]. Briefly, 
animals were placed onto small round platforms (=6.5 cm, called ‘small pot’) situated 
in the middle of a round water tank (=41 cm) for 72 h, at lights on. The surface of the 
platform was 0.5 cm above the water level. The control rats were kept single 
undisturbed in their single home cages (‘HC controls’). As lack of the muscle tone is 
typical in REM sleep, animals on the platforms fall into the water immediately as they 
switch to REM sleep. Following the 72h-long deprivation, one group of the animals had 
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been replaced into their singe cages and kept undisturbed for a 3h-long ‘REM sleep 
rebound’.  
 
Rats on the platforms were fed ad libitum without restriction using a waterproof food 
supplier unit at a distance easy to approach. Body weight change and food intake of rats 
during the time spent on the platforms were measured.  
7.2.2. Immunohistochemistry (IHC) 
Following the procedure, rats anesthetized with sodium pentobarbital 
(Nembutal, 35 mg/kg, i.p.; CEVA-Phylaxia) were sacrificed by transcardial perfusion 
using 4% paraformaldehyde in 0.1 M phosphate buffered saline, pH = 7.4 (PBS). Fixed 
tissue was postfixed at 4 °C overnight and cryoprotected in 20% sucrose in 0.1M 
phosphate buffer pH = 7.4 (PB) overnight before freezing. Then, hypothalami were cut 
into 50-μm-thick serial coronal sections on a frigomobile (Frigomobile; Reichert-Jung, 
Vienna, Austria) for immunohistochemical procedure.  
The morphometrical analysis in Experiment 1 and 2 was performed in the following 
hypothalamic areas (Paxinos and Watson 2007): 
 zona incerta/subzona incerta (ZI) 
 lateral hypothalamic area (LH) 
 perifornical area (PFA) 
7.2.2.1. Experiment 1. - MCH/Fos double immunostaining and morphometry analysis 
First, sections were permeabilized with 0.5 % Triton X-100 for 1 h. The 
endogenous peroxidase activity and the nonspecific antigen binding sites were blocked 
with the incubation of the sections in 3 % hydrogen-peroxide solution and in 10% 
normal goat serum for 15 min and for 1 h, respectively. For immunostaining, solutions 
were dissolved in PBS and the primary antibodies were applied for 2 days at 4 °C; all 
the other incubations were performed at room temperature for 1h. Between the 
incubation steps, sections were washed for 3×10 min in PB.  
Following these steps, the sections were incubated in rabbit anti-Fos (1:30,000, 
in PB; Santa Cruz Biotechnology, Inc., Heidelberg, Germany) primary antibody, and 
then in biotinylated goat anti-rabbit IgG (1:1,000) and in avidin–biotin–peroxidise 
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complex (ABC, 1:500) for 1 h in both solutions (both from Vector Laboratories, 
Burlingame, CA, USA). The immunostaining was visualized by nickel-enhanced 
diaminobenzidine (NiDAB) chromogen resulting in a dark-blue reaction product. Then, 
MHC immunostainings were performed in the same way as the first one, but in this case 
using rabbit anti-MCH as primary antibody (1:10,000 in 3 % BSA/0.5 % Triton X-100 
from Phoenix Europe GmbH, Karlsruhe, Germany) and DAB, with chromogen resulting 
a brown reaction product. Finally, the sections were collected on gelatin-coated slides, 
dehydrated, and mounted with DPX Mountant (Sigma-Aldrich, Budapest, Hungary) 
mounting medium. 
During the morphomety analysis, we determined the quantity of total number of 
the MCH-immunoreactive (MCH-IR or MCH-positive) neurons and the total amount of 
the Fos-immunoreactive (Fos-IR or Fos-positive) nuclei as well as the total amount of 
the MCH/Fos double positive neurons bilaterally in the areas of interest. For that we 
used at least five 50-μm-thick coronal sections per animal between bregma −2.5 and 
−3.5 mm caudally to bregma using a Visopan microscope (No. 361977; Reichert, 
Austria). In each section, four randomly selected non-overlapping areas were quantified 
(0.64 mm
2
 altogether) under a 40× objective by the same observer in all cases. Finally, 
the number of cells was calculated to cells per square millimeter values. For further 
analysis, we calculated the ratio of the activated (Fos-positive) portion of the MCH-
immunoreactive (MCH-IR or MCH-positive) neurons, namely the percent of the 
MCH/Fos double positive neurons. 
7.2.2.2. Experiment 2. - MCH/nesfatin/Fos triple immunolabeling and morphometry 
analysis 
The starting steps of this immunostaining was performed similarly to 
Experiment 1, including blocking the endogenous peroxidase activity and non-specific 
binding sites (here in 1% BSA), increasing permeability of the cell membranes and 
diluting primary and other antibodies. Sections were washed 3×5 min in PBS following 
each incubation step. To block peroxidase enzyme used for visualization previously, 
and to prevent species cross-reactions caused by primary antibodies raised in the same 
hosts, sections were microwave-treated in 0.1 M citric-acid (pH = 6.0) for 5 min after 
each immunostaining [158]. Fos immunostaining was performed using rabbit anti-Fos 
primary antibody (1:30,000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
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and anti-rabbit IgG polymer-HRP (Millipore, Budapest, Hungary) secondary antibody. 
The immunostaining was visualized by FITC-conjugated tyramide according to 
manufacturer’s instructions (Invitrogen, Budapest, Hungary). Next, sections were 
incubated in rabbit anti-nesfatin (1:24,000, Phoenix Pharmaceuticals, Inc., Burlingame, 
CA, USA) and again in anti-rabbit IgG polymer-HRP (Millipore). The second 
immunostaining was developed by tyramide-conjugated Alexa Fluor 568 (Invitrogen). 
In case of triple immunostainings for Fos, nesfatin and MCH, rabbit anti-MCH was 
applied (1:10,000, Phoenix Europe GmbH), followed by incubation in biotinylated anti-
rabbit IgG as secondary antibody (1:1,000, Vector Laboratories, Inc., Burlingame, CA, 
USA) and in extravidine-peroxidase (1:1,000, Sigma). The MCH antigen was visualized 
by tyramide-conjugated biotin (Invitrogen) and Streptavidin-Cy5 (1:1000, Jackson 
ImmunoResearch Europe Ltd, Newmarket, Suffolk, UK). Sections were mounted on 
non-coated slides, air - dried and coverslipped with DPX (Sigma). 
For morphometry analysis, images were captured bilaterally using a 20X 
objective (S Fluor 20X/0.75, ∞/0.17, WD1.0) on 3–5 sections per animal by a Nicon 
Eclipse E800 microscope attached to a Bio-Rad Radiance 2100 Rainbow confocal 
scanning system by sequential scanning. Cell counts and determination of co - 
localization were made using the AnalySIS Pro 3.2 program (Olympus, Soft Imaging 
Solutions GmbH, Münster, Germany), by simultaneous examination of the greyscale 
images of the separated channels and the coloured overlay picture. To identify neurons 
in the pictures, a numbered grid of the same size was placed over the overlay picture 
and the greyscale pictures of the separated channels. Only neurons with visible cell 
nuclei were counted.  
For further analysis, we calculated the percentage of (i) the nesfatin/MCH 
double positive neurons among the nesfatin positive ones, (ii) the Fos-positive nesfatin 
neurons within the single nesfatin and (iii) the Fos/nesfatin/MCH within the 
nesfatin/MCH double positive subpopulations, per animal.  
7.2.3. Drug treatment 
In order to investigate how an increased serotonergic tone influences the 
neuronal activation of MCH- and nesfatin-positive neuron populations, we applied 10 
mg/kg escitalopram-oxalate (dissolved in saline, provided by EGIS Plc., Hungary) the 
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highly selective serotonin reuptake inhibitor (SSRI) antidepressant, in acute 
intraperitoneal (ip) injection. Escitalopram (or saline) was injected prior to ‘REM sleep 
rebound’ (‘rebound’) period in Experiment 1. 
7.2.4. Experimental groups 
The following groups were used in  
Experiment 1 (Figure 5, A): 
 Small pot rebound – vehicle group (SPR-veh): sacrificed after spending 72h 
on small platform followed by a 3h-long ‘REM sleep rebound’ (3h after light on, 
on Day 4); injected with vehicle (saline) prior to ‘rebound’ period, (n=9) 
 Home cage – vehicle group (HC-veh): kept undisturbed in the home cages, and 
sacrificed at the same time like SPR groups (3h after light on, on Day 4); 
injected with vehicle (saline), (n=7) 
 Small pot rebound – SSRI group (SPR-SSRI): sacrificed after spending 72h 
on small platform followed by a 3h-long ‘REM sleep rebound’(3h after light on, 
on Day 4); injected with SSRI prior to ‘rebound’ period (n=9) 
 Home cage – SSRI group (HC-SSRI): kept undisturbed in the home cages, and 
sacrificed at the same time like SPR groups (3h after light on, on Day 4); 
injected with SSRI, (n=7) 
 
Experiment 2 (Figure 5, B): 
 Small pot deprived group (SPD): sacrificed after spending 72h on small 
platform (at light on), (n=5) 
 Small pot rebound group (SPR): sacrificed after spending 72h on small 
platform followed by a 3h-long ‘REM sleep rebound’(3h after light on), (n=5) 
 Home cage group (HC): kept undisturbed in their home cages, and sacrificed at 
the same time like SPR group (3h after light on), (n=5) 
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Figure 5. Schematic illustration of the flower pot sleep deprivation method in 
Experiment 1 and Experiment 2 (A-B). In Experiment 1 (A), rats were injected with 10 
mg/kg ip SSRI (escitalopram) or vehicle (VEH, saline) just prior to the 3h-long sleep. 
Following the 72h-long REM sleep deprivation or home cage stay (in case of controls) 
during Day 1 – Day 3, animals were allowed to sleep in their own cages for 3h on Day 
4. The ‘REM sleep rebound’ and home cage animals were sacrificed at the same time 
(ca. 13:10 h). In Experiment 2 (B), one subgroup of the sleep deprived animals was 
sacrificed immediately following the 72 h deprivation (ca. 10:00), and another subgroup 
of them was sacrificed after the 3h ‘rebound sleep’ (ca. 13:10 h). Home cage animals 
were sacrificed at the same time with ‘REM sleep-rebound’ rats. All animals were 
perfused transcardially for immunohistochemical procedure.  
 
7.3. Electroencephalography (EEG): Experiment 3 and 4 
In order to investigate the effect of exogenously administered nesfatin-1 on the 
EEG pattern of sleep-wake cycle and the quantitative EEG power spectra, as well as to 
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compare the quantitative power spectra of nesfatin-1 and escitalopram, we performed 
EEG study.  
7.3.1. EEG surgery 
Rats (n=6/group) were equipped chronically with electroencephalographic 
(EEG) and electromyographic (EMG) electrodes for EEG recordings, as described 
earlier (Kantor, 2004). Stereotaxic surgery was performed under 2% halothane 
anesthesia (using Fluotec 3 halothane vaporizer). Briefly, stainless steel screw 
electrodes were implanted epidurally over the left frontal motor cortex (coordinates: 
anterior-posterior (A-P): 2.0 mm from bregma, lateral (L): 2.0 mm to the midline, [159] 
the left parietal cortex (A-P: 2.0 mm from lambda, L: 2.0 mm) for fronto-parietal EEG 
recordings, and a ground electrode was placed over the cerebellum. In addition, EMG 
electrodes (stainless steel spring electrodes embedded in silicon rubber, Plastics One 
Inc., Roanoke, VA, USA) were placed into the muscles of the neck. To record motor 
activity of the animal, electromagnetic transducers were used in which potentials were 
generated by movement of the recording cable [160].  
In case of Experiment 3, during the surgery, for the icv injections, we implanted 
a plastic cannula into the right lateral ventricle (coordinates: A-P: −0.8 mm to the 
bregma level, L: 2.0 mm, and ventral: 4.0 mm below the skull surface). The cannula and 
the EEG electrodes were anchored to the skull with dental cement (Spofa Dental a.s., 
Markova, Czeh Republic). A stainless steel obturator was inserted into the guide 
cannula and was kept patent until use. The placement of the cannula was verified at the 
end of the study by injecting 10 nM/3 µl of angiotensin II icv [161-163]. Only animals 
reacting with an intensive (3 ml water intake in 30 min) drinking response were 
included in the study. 
After surgery, rats were kept in single cages in the recording chamber, and were allowed 
to recover for 7 days. Animals were then habituated to the recording conditions for five 
days before experiment started by attaching them to the polygraph using a flexible 
recording cable and an electric swivel, fixed above the cages, permitting free 
movements for the animal. During the recovery and the habituation period to the 
recording conditions, animals were also handled daily to minimize future experimental 
stress, as described earlier [164].  
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7.3.2. EEG data acquisition 
The signals were amplified (amplification factors ca. 5,000 for EEG and motor 
activity, 20,000 for EMG), conditioned by analogue filters (filtering below 0.50 Hz and 
above 60 Hz at 6dB octave
-1
) and subjected to analogue to digital conversion with a 
sampling rate of 128 Hz. The digitalized signals are stored on the computer for further 
analysis.  
7.3.3. Design of Experiment 3 and 4 
7.3.3.1. Experiment 3. – Effect of centrally administered nesfatin-1 on the EEG 
On the day of the experiment, 25 pmol/5 µl of nesfatin-1 dissolved in 
physiological saline was injected into the lateral ventricle of rats at light onset (at 10:00 
am.). Control rats received 5 µl physiological saline icv. After injections, animals 
returned to their home cages and EEG, EMG, motility and video was recorded for 24 h. 
Considering the possible effect of stress on vigilance, caused by the icv - procedure, 
despite former habituation, the 1
st
 h of all EEG recordings has been excluded from the 
analysis. Thus, the 2
nd
-6
th
 h of passive (light) phase, as well as the first six hours of 
active (dark) phase (13
th
-18
th
 h) have been included in the sleep analysis. See the 
experimental design on Figure 6.  
 
 
 
Figure 6. Experimental design of the electroencephalographic (EEG) study in 
Experiment 3: the effect of nesfatin-1 on the sleep-wake cycle and EEG spectra. 
EEG recording was performed for 24h following the intracerebroventricular (icv) 
administration of nesfatin-1 or vehicle (VEH, saline) in the passive phase at light on 
(10:00 h). Scoring of the EEG recordings were performed during the 2
nd
-6
th
 h of passive 
phase and the first 6 h of active phase (13
th
-18
th
 h).  
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7.3.3.2. Experiment 4. – Effect of two doses of intraperitoneally injected escitalopram 
on EEG 
On the day of the experiment, 2 or 10 mg/kg escitalopram-oxalate dissolved in 
vehicle [solution of 10% (2-hydroxypropyl)-β-cyclodextrin, Sigma-Aldrich] was 
injected ip at light onset (at 10:00 am.). Control rats received vehicle ip. in the same 
volume (1ml/kg body weight). After injections, animals returned to their home cages 
and EEG, EMG, motility as well as video were recorded for 24 h. The quantitative EEG 
spectra of the first three hours were evaluated, compared to control.  
 
The following experimental groups were used:  
 Escitalopram 2 mg/kg  (n=13) 
 Escitalopram 10 mg/kg  (n=12) 
 Vehicle    (n=9) 
7.3.4. Sleep scoring 
The vigilance states were classified by SleepSign for Animal sleep analysis 
software (Kissei Comtec America, Inc., USA) for 4 sec periods using conventional 
criteria [160, 165] followed by visual supervision of an expert scorer who was blind to 
experimental treatment. We differentiated the following vigilance stages:  
1) Wakefulness; EEG is characterized by low amplitude activity at beta (14–30 
Hz), alpha (8–13 Hz) and theta (5–9 Hz) frequencies; according to high or low EMG 
and motor activity, wakefulness can be subdivided into active- (AW) and passive 
wakefulness (PW), respectively 
2) REM sleep; low amplitude and high frequency EEG activity with regular 
theta waves (5–9 Hz) accompanied by silent EMG and motor activity with occasional 
twitching 
  3) Intermediate stage of sleep (IS); a brief stage just prior to REM sleep and 
sometimes just after it, characterized by unusual association of high amplitude spindles 
(mean 12.5 Hz) and low-frequency (mean 5.4 Hz) theta rhythm 
4) Non-REM sleep; slow cortical waves (0.5–4 Hz) accompanied by reduced 
EMG and motor activity. Depending on the amount delta power non-REM sleep can be 
subdivide into light and deep slow wave sleep (SWS1 and SWS2, respectively) [160].  
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In sleep analysis after icv nesfatin-1 treatment, the following vigilance 
parameters were calculated: time spent AW and PW, REM sleep, SWS1 and SWS2 per 
hour. Additionally, specific parameters were calculated, namely, the number and the 
average duration of episodes in REM sleep, IS, SWS1 and SWS2. An episode of any 
vigilance stages was defined as an item lasting at least 4 sec and not interrupted by any 
other vigilance stages for longer than 4 sec. Sleep fragmentation was defined as the 
number of wake epochs (AW, PW) after a sleep stage (SWS1, SWS2, REM and IS).  
7.3.5. EEG power spectra analysis 
EEG power spectra (quantitative EEG spectra, qEEG) were computed for 
consecutive 4s epochs in the frequency range of 0.25-60 Hz (using fast Fourier 
transformation routine, Hanning window; frequency resolution 0.25 Hz). Adjacent 0.25 
Hz bins were summed into 1 Hz bins. Bins are marked with their upper limits; therefore, 
e.g. 2 Hz refers to 1.25-2.00 Hz. Epochs with artifacts were omitted from the EEG 
power analysis. The EEG power values of the consecutive epochs were averaged in the 
summarized 2
nd
-3
rd
 h of passive/light phase to obtain the power density values for the 
following vigilance stages: AW, PW, SWS1, SWS2 and REMS. To reduce individual 
differences, we normalized data dividing the EEG power values at each Hz of frequency 
by the summed whole spectra (0.25-60 Hz) in case of each animal.  
7.3.6. Heat map spectra 
To compare the spectral distribution of EEG power of different vigilance stages 
in the nesfatin- and escitalopram-treated groups in the summarized 2
nd
-3
rd
 h of passive 
phase, we adapted ‘state space analysis technique’ (modified after Diniz-Behn et al. 
[166]). We plotted EEG power values of each epoch (4s interval) as Ratio 1 (6.5-9/0.5-9 
Hz) on the abscissa and Ratio 2 (0.5-20/0.5-60 Hz) on the ordinate, which defined 2-
dimensional spectra separating three clusters, correspond to the conventionally 
determined vigilance stages, namely REM sleep, non-REM sleep and wake. Ratio 1 was 
determined to emphasize high theta (6.5-9 Hz) activity which dominates REM sleep in 
rodents. Although this range is slightly different from that considered generally as theta 
range in rat (5-9 Hz), we used the 6.5-9 Hz range, as cluster-separation was more 
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efficient using this one. Ratio 2 (0.3-20/0.3-55 Hz) was developed to separate non-REM 
sleep and wake [166]. We adopted this range with little modification (0.5-20/0.5-60 
Hz), as our setup measures the frequency range of 0.5-60 Hz. To visualize not only the 
dispersion but also the density of EEG power data of clusters, we created a heat map 
with centroids, where red colour shows higher, while blue colour shows lower density 
of epochs at a given point. The general positions of ‘state space clusters’ associated with 
REM sleep, non-REM sleep and wake stages is considered to be conserved [21]. We 
marked the stage cluster centroids with white and black dots in the control and the 
treated groups, respectively, to visualize both the direction and the degree of the shift 
from the ‘control position’ as a result of treatment, demonstrating the alteration of EEG 
power density. Centroids were calculated by averaging EEG power data (arithmetic 
mean calculated from the x and y coordinates of each epoch) of animals within control 
and (nesfatin-1- or escitalopram-) treated groups in passive phase. To perform heat map 
spectra from EEG power data Matlab software was used.  
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7.4. Statistics 
We used STATISTICA 7.0 program (Statsoft Inc., Tulsa, OK, USA) to perform 
statistics. For the evaluation of the IHC data, one-way analysis of variance (ANOVA) or 
(in case of inhomogeneous variances) one-way ANOVA on Ranks were used, followed 
by all pairwise comparisons with Dunn’s or Tukey’s method, respectively. Data in all 
figures are expressed as mean ± standard error of mean (SEM). 
Sleep data of different vigilance stages, summarized hourly, were evaluated by 
two-way ANOVA for repeated measures (repeated factor: time). In case of 
inhomogeneous variances of the experimental groups, repeated measures ANOVA on 
Ranks was performed. For post hoc analysis, Tukey HSD was used.  
The effect of nesfatin-1 and (2 or 10 mg/kg) escitalopram on the power spectra, 
compared to vehicle, was analysed in each vigilance stage, during the summarized 2
nd
-
3
rd
 h using repeated measure two-way ANOVA with two main factors: ‘treatment’ and 
‘frequency bands’ (repeated factor). For multiple post hoc comparisons, Holm-Sidak 
method was used. We indicated significant multiple comparison results even if the RM 
ANOVA had no significant main effect, as Holm-Sidak method is not restricted to use 
as a follow-up test after ANOVA [167].  
Regarding the heat map spectra, shifts in the centroids were evaluated with two-
tailed unpaired t-tests (nesfatin-1-treated group vs. control) as well as with one-way 
ANOVA followed by Tukey's multiple comparison test or (in case of inhomogeneous 
variances) Kruskal-Wallis test followed by Dunn’s multiple comparison (2 mg/kg and 
10 mg/kg escitalopram-treated groups vs. control). To test the equal variances Brown-
Forsythe test was used. The results are presented as mean ± (SEM). 
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8. Results 
8.1. Immunohistochemistry 
8.1.1. Experiment 1: Activation of MCH neuron population as a result of ‘REM 
sleep rebound’ in different hypothalamic/thalamic nuclei  
We found that in the vehicle-treated small-pot REM sleep-deprived group, 
‘REM sleep rebound’ (SPR-veh) caused a significant increase in the neuronal (Fos) 
activation of the MCH-containing neurons in different hypothalamic/thalamic 
structures, like the ZI, the LH and the PFA including the perifornical nucleus itself 
(Figure 7, A, B, C, respectively), compared to vehicle-treated home cage (HC-veh) 
group. In the SPR-veh group, the ratio of Fos-positivity in the MCH-IR neurons was 
65.69±6.98% in the ZI, 64.99±5.47% in the LH and 56.24±7.15% in the PFA. In the 
HC-veh group, the Fos-positive rate of MCH-containing neurons was quite low (less 
than 2 % in all the investigated areas). The effect of Tukey’s post hoc comparisons 
following significant one-way ANOVA results (see later) are indicated on Figure 7, A, 
B, C.   
We also investigated whether an increased serotonergic tone is able to influence 
this strong neuronal activation of the MCH-positive neurons. For that, escitalopram, a 
highly selective SSRI antidepressant was applied in acute ip injections (or vehicle for 
controls) prior to the beginning of the 3h-long ‘REM sleep rebound’ (for experimental 
design, see Figure 5, A in Methods). According to our results, escitalopram significantly 
decreased the rate of activated MCH-containing neurons in the ZI, LH and PFA. In the 
SPR-SSRI group, the Fos-ratio of MCH-neurons was the following: ZI: 56.33±11.32%, 
LH: 52.03±8.52% and PFA: 46.08±9.79%.  
One-way ANOVA results for the comparison of the four experimental groups 
(SPR-veh, SPR-SSRI, HC-veh and HC-SSRI) in the investigated areas are the 
following: ZI: F(3,28)=187.3, p<0.0001; LH: F(3,28)=271.8, p<0.0001; PeF: F(3,28)=161.3, 
p<0.0001. Tukey’s post hoc results (depicted on Figure 7.) show that escitalopram 
markedly reduced the rate of MCH/Fos in the SPR-SSRI group in all the investigated 
areas, compared to the SPR-veh group. 
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On the contrary, we did not find any difference in the neuronal activation of 
MCH-positive neurons between the HC-SSRI and HC-veh groups in any of the 
investigated structures (Figure 7, A, B and C). On the other hand, two-way ANOVA 
showed a significant interaction between the ‘REM sleep rebound’ and escitalopram 
treatment in the ratio of MCH/Fos in both the LH (F(1,28)=15.37, p<0.001) and the PFA 
(F(1,28)=4.459, p<0.05), although in the ZI, we found only a tendency (F(1,28)=3.875, 
p=0.0590). However, the total number of MCH-IR neurons (Fos–positive and –negative 
together) was not affected by the experimental procedures (Figure, 7, D). Representative 
figures about the MCH/Fos immunostainings investigating three hypothalamic 
structures in the four experimental groups are depicted on Figure 8. 
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Figure 7. The neuronal (Fos) activation of the melanin-concentrating hormone 
(MCH)-containing neuronal cell population of different hypothalamic/thalamic 
structures as a result of ‘REM sleep rebound’ and selective serotonin reuptake 
inhibitor (SSRI) treatment and their combination. The ratio of MCH/Fos  in the (A) 
zona incerta/subzona incerta, (B) the lateral hypothalamic area and (C) the perifornical 
area in the
 
vehicle- and SSRI-treated home cage [HC-veh (n=7) and HC-SSRI (n=7), 
respectively] and ‘REM sleep rebound’ [SPR-veh (n=9) and SPR-SSRI (n=9), 
respectively] groups. The total amount of MCH-immunoreactive (IR) neurons per mm
2 
(D)
 
was not influenced by the experimental procedure in the investigated nuclei. Note, 
that Fos-positivity of MCH neurons was significantly increased by ‘REM sleep 
rebound’, however, SSRI-treatment decreased it in all the investigated structures. 
Results of post hoc comparisons: *: p<0.05 and **: p<0.01 compared to SPR-veh, #: 
p<0.05 compared to HC-veh.  
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Figure 8. Illustrative pictures 
about the MCH/Fos double 
immunostaining visualizing the 
neuronal (Fos, bluish nuclei) 
activation of the melanin-
concentrating hormone (MCH)-
expressing neurons (brown 
cytoplasmatic staining) in 
different hypothalamic nuclei in 
four experimental groups as a 
result of ’REM sleep rebound’ 
and combined SSRI-treatment 
(A-P). A-D, Lower magnification 
pictures of the presented sections 
in the  experimental groups (A, 
vehicle-treated home cage; B, 
SSRI- treated home cage; C, 
vehicle-treated ‘small pot REM 
sleep-rebound’; SSRI-treated 
‘small pot REM sleep-rebound’). 
Higher magnification of the boxed 
zones on A, B, C and D pictures 
show the areas of interest: ZI: zona 
incerta/subzona incerta (on E, H, K 
and N panels), LH: lateral 
hypothalamic area (on F, I, L and 
O panels) and PFA: perifornical 
area (on G, J, M and P panels). 
Note the high rate of MCH/Fos 
double-labeled cells in the ‘REM 
sleep rebound’ groups (C, D as 
well as K-M and N-P). However, 
the decrease in MCH/Fos ratio 
caused by escitalopram-treatment 
(panel D and N-P vs. panel C and 
K-M) is not apparent at this 
magnification (D and N-P). In the 
HC groups, MCH/Fos double-
labeled cells among MCH-
immunoreactive neurons are 
almost absent (A-M). Scale bar = 
100 μm. The boxed zones are 100 
μm×100 μm.  
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8.1.2. Experiment 2: Activation of nesfatin-containing neurons in different 
hypothalamic/thalamic structures as a result of ’REM sleep rebound’ 
Regarding data in the literature, namely, (i) all MCH-positive neurons co-
express the neuropeptide nesfatin-1/NUCB2 (nesfatin), (ii) but only a portion of 
nesfatin-IR neurons co-express MCH [128], moreover, (iii) there is a strong connection 
between the activation of MCH-neuronal population and REM sleep, we aimed to 
investigate how the MCH-positive and -negative nesfatin-IR neuronal cell populations 
respond to ‘REM sleep rebound’.  
First, we determined the degree of co-localization of MCH and nesfatin in HC 
controls. The rate of co-localization showed slight differences in the investigated areas: 
ZI: 81.9±1.7%, LH: 75.4±2.1%, PFA: 66.2±4.8% and these ratios were not affected by 
the ‘REM sleep rebound’.  
Investigating the MCH/nesfatin co-expressing neuron populations in the ZI, LH 
and PFA, we found that neuronal (Fos) activation was minimal (less than 0.5%) both in 
HC controls and the SPD group. However, ‘REM sleep rebound’ caused a significant 
elevation in the rate of neuronal activation regardless of the area investigated (ZI, 
86.9±2.9%, H=11.04, p<0.01; LH: 79.0±1.8%, H=9.673, p<0.01 and PFA: 78.3±2.7%, 
F(2,12)=818.1, p<0.0001, Figure 9, A).  
However, the MCH-negative nesfatin neurons showed higher activity in HC and 
SPD groups, particularly in the PFA (24±8.1% and 39.4±7.4% in HC and SPD groups, 
respectively). ‘REM sleep rebound’ caused an increase in the Fos positivity, although it 
reached the level of statistical significance only in the LH (SPR: 37.6±4.8% vs. HC: 
6±2.4%, F(2,12)=21.12, p<0.01, Figure, 9, B).  For the illustration of nesfatin/MCH/Fos 
triple immunostaining, see Figure 10. The results of Tukey’s or Dunn’s post hoc tests 
are shown on Figure 9, A and B. 
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Figure 9. The neuronal (Fos) activation of the melanin-concentrating hormone 
(MCH)-positive and MCH-negative nesfatin cell populations of different 
hypothalamic/thalamic structures as a result of REM sleep deprivation and ‘REM 
sleep rebound’ (A-B). The following experimental groups were used: small pot REM 
sleep deprived (SPD, n=5), small pot ‘REM sleep rebound’ (SPR, n=5) and home cage 
controls (HC, n=5). Regarding the MCH-positive nesfatin-population (A), minimal 
(<0.5%) neuronal activation was detected in HC and SPD groups, while ‘REM sleep 
rebound’ caused a markedly elevated Fos activation in the zona incerta/subzona incerta 
(ZI), the lateral hypothalamic area (LH) and in the perifornical area (PFA). In the MCH-
negative nesfatin population (B), in HC and SPD groups, a higher Fos activity was 
detected, particularly in the PFA. However, ‘REM sleep rebound’ caused a significant 
elevation in Fos-positivity only in the LH. Results of post hoc comparisons: *: p<0.05, 
**: p<0.01 compared to HC controls.  
 
Similarly to the effect of escitalopram on the Fos-positivity of the MCH-IR 
neuron-population, escitalopram also decreased the rate of neuronal activation in the 
nesfatin-positive neuron population. The average reduction of nesfatin/Fos was 12.2% 
(n=3), however, due to the small number of cases we did not have enough statistical 
power to evaluate the effect of escitalopram in this case.  
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Figure 10. Photomicrographs 
illustrating the results of triple 
fluorescent immunostaining, 
visualizing the melanin-
concentrating hormone (MCH)-
positive and –negative nesfatin-
1/NUCB2 (nesfatin) neurons in the 
lateral hypothalamic area of home 
cage (A) and ’REM sleep rebound’ 
group (B). The staining was the 
following: blue for MCH, red for 
nesfatin and green for Fos. On the 
pictures, nesfatin/MCH double-
positive neurons are pink (arrows), 
MCH - negative nesfatin neurons are 
red (arrowheads). Activated 
nesfatin/MCH neurons show white 
nuclei, activated nesfatin - positive, 
but MCH - negative neurons have 
yellow nuclei. Note, that the majority 
of the MCH - positive nesfatin 
neurons (arrows) are activated by 
rebound (Fos - positive), while only a 
few of the MCH - negative nesfatin 
neurons (arrowheads) showed Fos - 
positivity. Scale bar: 100 μm. Data are 
shown as mean ± SEM, n = 5. 
 
A 
B 
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8.2. Electroencephalography (EEG) 
8.2.1. The effect of exogenously administered nesfatin-1 on the architecture of 
sleep-wake cycle 
The high neuronal activity of the MCH/nesfatin-co-expressing cell population, 
as a result of ‘REM sleep rebound’, raised the question, whether nesfatin-1 
neuropeptide, the N-terminal fragment of the nucleobindin 2 protein (NUCB2) itself, 
can influence sleep-wake cycle or not. To investigate this question, we injected 25 pmol 
nesfatin-1 icv at the beginning of passive phase, and analysed the architecture of sleep-
wake cycle (i) during the 2
nd
-6
th
 h after injection, and (ii) for the possible rebound 
effect, at the beginning of the active phase (13
th
-18
th
 h, see chapter 8.2.1.2.). 
8.2.1.1. Passive phase: 2
nd
-6
th
 hours following central injection 
We found that icv nesfatin-1 significantly elevated sleep fragmentation, namely 
the number of awakenings (F(1,10)=5.1046, p<0.05). However, the amount of total sleep 
time showed only a tendency to decrease during the five investigated hours of passive 
phase (p = 0.0587).  
Regarding the effect of nesfatin-1 on different stages of sleep-wake cycle, we 
observed the most apparent change in REM sleep. It decreased the time spent in REM 
sleep significantly (F(1,10) = 18.99, p<0.001), compared to controls. This reduction was 
approximately 60% in the 2
nd
 h, but in the next three hours, the decrease in REM sleep 
reached an approximate value of 90%, while in the 6
th
 h it was ca. 70% (Fig. 11, A). 
Due to the REM sleep-suppressing effect of nesfatin-1, we could calculate REM sleep 
data of only four animals in the nesfatin-1-treated group. The amount of IS showed a 
similar decrease, with the lowest value in the 3
rd
 h (F(1,10) = 11.04, p<0.01, Fig. 11, B).  
Considering the time spent in non-REM sleep, we differentiated light slow wave 
sleep (SWS1) and deep slow wave sleep (SWS2). In SWS1, a significant time × 
treatment interaction (F(2,20) = 4.092, p<0.05) was found, when repeated measure 
ANOVA was performed including the 2
nd
, 3
rd
 and 4
th
 hours only. The significant results 
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of the post hoc comparisons are shown on Fig. 11, C. In SWS2, we found no alteration 
in any investigated hours, compared to control (Fig. 11, D). 
In wakefulness, the amount of PW elevated markedly (F(1,10) = 8.955, p<0.05, 
Fig. 11, E), while the time spent in AW revealed no alteration (Fig. 11, F).  
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Figure 11. The effect of intracerebroventricularly (icv) administered nesfatin-1 on 
the architecture of sleep-wake cycle (A-F). (A, B) The time spent in rapid eye 
movement (REM) sleep and intermediate stage of sleep (IS), (C, D) light and deep slow 
wave sleep (SWS1 and SWS2, respectively), as well as (E, F) active and passive wake, 
respectively in the 2
nd–6th hours of passive (light) phase, compared to (icv vehicle) 
control group. Note, that nesfatin-1 affected REM sleep, PW and IS markedly and 
SWS1 for a short time, while SWS2 did not show any alteration. Data are presented as 
mean ± SEM, n = 6 per group, p*<0.05, p**<0.01. Due to the REM-suppressing effect 
of nesfatin-1, in the nesfatin-1-treated group, REM amount was calculated using only 
n=4 data. 
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The REM sleep- and IS-declining effect of nesfatin-1 seemed to be apparent also 
in the number and the average duration of the episodes in both REMS (F(1,10) = 10.45, 
p<0.01 and F(1,10) = 12.81, p<0.01, Fig. 12, A and B, respectively) and IS (F(1,10) = 7.18, 
p<0.05 and F(1,10) = 6.99, p<0.05, Fig. 12, C and D, respectively). 
Noteworthy, that the increase of SWS1 and PW (Figure 11, C and E) was 
parallel to the elevation of episode-numbers generally (F(1,10) = 9.87, p<0.05, Fig. 13, A 
and (F(1,10) = 6.46, p<0.05, Fig. 12, E, respectively), although the average episode-
durations of these stages were unaffected (Fig. 13, B and 12, F, respectively). However, 
the time spent in SWS2 showed no alteration despite the significant increase in the 
number of episodes in the 4th h (Fig. 13, C).  
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Figure 12. The effect of intracerebroventricularly (icv) administered nesfatin-1 on 
the number and average duration of episodes in different vigilance stages during 
the 2
nd
-6
th
 h of passive (light) phase (A-F). The number of episodes in rapid eye 
movement (REM) sleep (A), intermediate stage of sleep (IS, C) and passive wake (PW, 
E), as well as the average duration (Avg. duration) of episodes in REM sleep (B), IS (D) 
and PW (F) vigilance stages, compared to (icv vehicle) control group. Note the definite 
decreasing effect of nesfatin-1 on both the number and average duration of REM sleep 
and IS episodes, while in case of PW, nesfatin-1 influenced only the number of 
episodes. Data are presented as mean ± SEM, n = 6 per group, p*<0.05, p**<0.01. Due 
to the REM-suppressing effect of nesfatin-1, in the nesfatin-1-treated group, REM data 
were calculated only using n=4 data.   
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Figure 13. The effect of intracerebroventricularly (icv) administered nesfatin-1 on 
the number and average duration of episodes in non-REM vigilance stages during 
the 2nd-6th h of passive (light) phase (A-D). The number of episodes in light and 
deep slow wave sleep (SWS1 and SWS2, A and C, respectively), and the average 
duration (Avg. duration) of SWS1 and SWS2 episodes (B and D, respectively), 
compared to (vehicle) control group. Note that despite the increasing effect of nesfatin-1 
on the episode number in both SWS1 and SWS2, the average duration of the episode 
was not changed. Data are presented as mean ± SEM, n = 6 per group, p*<0.05, 
p**<0.01. 
 
8.2.1.2. Active phase: 13
th
-18
th
 hours following central injection 
In contrast to the alterations of sleep time in passive phase, we found no 
significant change in the time spent in different vigilance stages in the active phase after 
25 pmol icv nesfatin-1 (Fig. 14). 
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Figure 14. The effect of intracerebroventricularly (icv) administered nesfatin-1 on 
the architecture of sleep-wake cycle in the active (dark) phase (13-18 h after 
injection, A-F). The time spent in active and passive wake (A and B), rapid eye 
movement (REM) sleep (C), light and deep slow wave sleep (SWS1 and SWS2, E and 
F, respectively), as well as number of awakenings (i.e. sleep fragmentation, D) during 
the 13-18 hours, compared to (vehicle) control group. Note that nesfatin-1 did not affect 
any of the vigilance stages significantly 13-18 h after the icv injection. Data are 
presented as mean ± SEM, n = 6 per group.  
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8.2.2. Comparison of the EEG power spectral data of nesfatin-1 and escitalopram 
using ‘state space analysis’ 
Based on the strong REM sleep-decreasing and passive wake-increasing effect 
of nesfatin-1 in our study, as well as literature data [143] have reported that icv nesfatin-
1 elevates the neuronal (Fos) activation of DRN and MRN serotonergic neurons, we 
raised the question whether the effect of icv nesfatin-1 can be associated with the 
serotonergic system or not. To address this issue, we investigated the possible 
similarities between the effect of nesfatin-1 and escitalopram, the selective SSRI 
antidepressant that is known to increase the serotonergic tone even after acute dosing. 
For this comparison, we used a relative new method [21], the ‘state space analysis’ 
technique (partly modified after Diniz-Behn et al. [166]).  
 
Figure 15. Demonstration of the basic concept of ‘state space analysis’ (modified 
after Diniz Behn et al. 2010 [170]. Each point on the plot represents a 4s-period (one 
epoch) of the sleep-wake cycle. Ratio 1 [6.5-9/0.5-9 Hz] and Ratio 2 [0.5-20/0.5-60 
Hz], calculated from the Fast Fourier Transformed EEG spectral data for each epoch, 
determines the position of each epoch, defining a 2D heat map. Ratio 1 (on the abscissa) 
is sensitive to high theta content, thus, it will effectively separate ‘REM sleep cluster’ 
from ‘wake cluster’ (with greater and lower amount of high theta power, respectively), 
while Ratio 2 separates ‘non-REM sleep cluster’ and ‘wake cluster’ based on the delta 
(0.5-4 Hz) and gamma power (30-60 Hz) content of epochs. White circles show the 
centroid of each cluster calculated from the arithmetic mean of the coordinates of EEG 
data points. The alteration in the extension, shape, density and centroid position of 
wake, non-REM and REM sleep clusters suggests changes in the EEG spectra as a 
result of treatment.  
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This technique enables visualization of the ‘topography’ of different vigilance 
stages using heat map spectra, moreover, can provide a way to observe general EEG 
spectral changes (‘shifts’) that are visible easily to the naked eye; and since the 
‘topography’ of non-REM, REM sleep and wake stages is based on their power spectral 
content, ‘state space analysis technique’ can be performed without sleep scoring (Figure 
15). However, in this chapter, I also demonstrate the traditional way of evaluation of 
EEG spectral data to reinforce results of ‘state space analysis technique’. 
To visualize the spectral distribution of EEG power data in different vigilance 
stages, we plotted EEG power data as Ratio 1 (6.5-9/0.5-9 Hz, on the x axis) and Ratio 2 
(0.5-20/0.5-60 Hz, on the y axis) defining two-dimensional spectra in the passive phase 
(Figure 16), in both the control and nesfatin-1-treated groups.  
These ratios separated EEG power data into clusters, corresponding to the 
conventionally determined vigilance stages, namely REM sleep, non-REM sleep and 
total wake (TW). To visualize not only the dispersion but also the density of power data, 
we created heat maps. The distribution of ‘state space clusters’ shows that nesfatin-1 
treatment significantly diminished the extent of the cluster corresponds to the REM 
sleep stage, compared to vehicle (Figure 16, C and A, respectively), reinforcing the 
REM sleep-inhibiting effect of icv nesfatin-1 (chapter 8.2.1.1.). The result of unpaired t-
test indicated a significant shift in the centroid position of ‘REM sleep cluster’ (t=2,337, 
df=8, p=0.0476), but we note, that due to the REM suppressing effect of nesfatin-1, 
REM sleep data were evaluated using only n=4 REM data (Figure 16, C). 
Since in the spectral analysis of passive phase, the most remarkable alteration 
was found in wakefulness, we demonstrated the heat map of TW separately (control and 
nesfatin-1-treated groups, Figure 16, B and D, respectively). These figures show that 
nesfatin-1 treatment caused a significant shift (p=0.0283, t=2.563, df=10) in the position 
of centroids (black circles) of the cluster corresponds to wake, compared to control 
(Figure 16, D and B, respectively). This shift to the left visualizes the significant theta 
power-reducing effect of nesfatin-1 in wakefulness. As Figure 16, C shows, icv 
nesfatin-1 caused no alteration in the centroid position of non-REM sleep evaluated 
with the ‘state space analysis’ technique.  
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Figure 16. Demonstration of the effect of icv-injected vehicle (A and B) or nesfatin-
1 (C and D) on the distributions and density of EEG power in passive (light) phase 
on a 2-dimensional ‘state space’ heat map (modified after Diniz Behn et al. 2010 
[170]). Plotting the spectral ratios of EEG power data (Ratio 1 [6.5-9/0.5-9 Hz] on the 
abscissa and Ratio 2 [0.5-20/0.5-60 Hz] on the ordinate) separated three distinct clusters 
of EEG power points: rapid eye movement (REM) sleep: right, non-REM sleep: upper 
left and total wake: lower left (circled on Fig. A). Each plot represents EEG power data 
(including n=6 animals per groups) of the 2-3h of recordings on colour-coded density 
maps (digits on the scale show the number of overlapping epochs on a given area). Note 
the obvious alterations in the distribution of clusters in the nesfatin-1-treated group (C) 
compared to the control group (A). Apparently, the cluster corresponds to REM sleep is 
significantly sparser, than that in the control. (B and D) Heat map spectra to visualize 
the alteration of EEG power in total wake in the nesftain-1-treated group separately (D), 
compared to control (B). Note that besides the higher density of wake epochs in the 
nesfatin-1-treated group, the centroid of wake is shifted to the left, compared to vehicle, 
possibly due to the decreased theta power in wake. Centroids (arithmetic mean of the 
given cluster) of the nesfatin-1- and vehicle-treated group are shown by black and white 
circles, respectively. The shift in the position of centroids as a result of nesfatin-1 
treatment in TW, compared to control is shown by the dotted line. We note, that due to 
the REM sleep-inhibiting effect in the nesfatin-1-treated group, REM sleep data were 
evaluated only from n=4 data.  
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In the active phase, we did not find significant shift in the centroid position of 
REM, non-REM sleep and wake stages versus control (data not shown). 
 
To compare the effect nesfatin-1 on ‘state space’ heat map spectra with the 
effect of a serotonergic-tone-increasing agent, we used 2 and 10 mg/kg escitalopram in 
ip injections at the beginning of passive phase. Figure 17 demonstrates that both the 
distribution and the density of the REM sleep-cluster shows a decrease after 2 and 10 
mg/kg escitalopram, compared to control (Figure 17, C, E and A, respectively). In case 
of the 10 mg/kg escitalopram-treated group, the area correspond to the ‘REM sleep 
cluster’ barely can be seen due to the strong REM sleep-inhibiting effect of 
escitalopram in this dose (Figure 17, E).  
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Figure 17. Demonstration of the effect of 2 and 10 mg/kg escitalopram or vehicle 
(of the summarized 2
nd
-3
rd
 h) on the distributions and density of EEG power in 
passive (light) phase on a 2-dimensional ‘state space’ heat map (modified after 
Diniz Behn et al. 2010 [166]). Plotting the spectral ratios of EEG power data (Ratio 1 
[6.5-9/0.5-9 Hz] on the abscissa and Ratio 2 [0.5-20/0.5-60 Hz] on the ordinate) 
separated three distinct clusters of EEG power points: rapid eye movement (REM) 
sleep: right, non-REM sleep: upper left and wake: lower left. Each plot represents EEG 
power data of 2 h recordings during the 2
nd
-3
rd
 h on colour-coded density maps (digits 
on the scale show the number of overlapping epochs on a given area). REM sleep 
cluster show a dose-dependent decrease in density and a definite shift to the left in the 
centroid-position of the clusters in the 2 and 10 mg/kg escitalopram-treated groups (C 
and E, respectively) vs. control (A). The enlarged ‘wake clusters’ are shown in the 2 and 
10 mg/kg escitalopram-treated groups (D and F, respectively) vs. control (B). The 
centroids of the vehicle- or the escitalopram-treated groups are indicated by white and 
black circles, respectively. The experimental groups included n=9 in the vehicle-treated 
group, n=13 in the 2mg/kg and n=12 rats in the 10 mg/kg escitalopram-treated groups, 
respectively. In case of the 10 mg/kg escitalopram-treated group, heat map spectrum for 
REM sleep was calculated from n=10 data, as two animals had no REM sleep data in 
the investigated 2h period.  
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In REM sleep stage, the shift in the centroid position was significant (Kruskal-
Wallis test: H=9.778, p=0.0075). However, Dunn’s multiple comparisons test showed 
that only the 10 mg/kg escitalopram treatment caused significant shift in the centroid 
position, compared to control (Fig. 18, A).  
On the contrary, the cluster corresponds to TW (‘wake cluster’) becomes 
apparently more populated in the 2 and 10 mg/kg escitalopram-treated groups, 
compared to vehicle (Fig. 17, C, E and A, respectively). We also can observe a notable 
shift to the left in the distribution and the centroid-position in both the 2 and 10 mg/kg 
escitalopram-treated groups, compared to vehicle (Fig. 17, D, F and B, respectively). 
According to one-way ANOVA, escitalopram caused a significant shift in the centroid-
position of TW (F(2,31)=6.732, p=0.0037). Tukey’s post hoc test showed significant 
shifts in the centroid position of TW cluster in both the 2 and 10 mg/kg-escitalopram-
treated groups, compared to control (Fig. 18, B).  
Besides the changes in the heat map spectra of TW and REM sleep in the 
escitalopram-treated groups, in non-REM stage, we did not find any alteration in the 
centroid positions (Figure 17, C and E vs. A, Figure 18, C).  
R E M  s le e p
D
is
ta
n
c
e
 f
r
o
m
 t
h
e
 o
r
ig
o
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
* *
T o ta l w a k e
D
is
ta
n
c
e
 f
r
o
m
 t
h
e
 o
r
ig
o
0 .0
0 .1
0 .2
0 .3
0 .4
* * *
n o n -R E M  s le e p
D
is
ta
n
c
e
 f
r
o
m
 t
h
e
 o
r
ig
o
0 .0
0 .1
0 .2
0 .3
0 .4
v e h ic le
E s c ita lo p ra m  2  m g /k g
E s c ita lo p ra m  1 0  m g /k g
A B C
 
Figure 18. Demonstration of the shifts in the centroid-positions (distance from the 
origo on x axis) in REM sleep, total wake (TW), and non-REM sleep vigilance-
stages on the ‘heat map spectra’ performed using ‘state space analysis technique’ 
in 2 (n=13) and 10 mg/kg (n=10-12) escitalopram-treated groups, compared to 
vehicle controls (n=9). Note that 10 mg/kg escitalopram caused a significant shift in 
both (rapid eye movement) REM sleep and wake stages (A and B), while in case of the 
2 mg/kg escitalopram, the shift was significant exclusively in TW, compared to control. 
However, in non-REM sleep, no alteration was found in any of the experimental groups 
(C). Data are presented as mean ± SEM. p*<0.05, p**<0.01.  
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As a short summary, ‘state space analysis’ indicated a shift to the left in the 
centroid positions on the x-axis of TW in the nesfatin-1- and escitalopram-treated 
groups, as well as in REM sleep in the escitalopram-treated groups, that suggests a 
possible decrease in theta power, as Ratio 2 is sensitive to the high theta-range (6.5-9 
Hz).  
8.2.3. Comparison of the EEG power spectra of nesfatin-1 and escitalopram using 
conventional spectral analysis 
As ‘state space’ analysis revealed similarities between the effect of nesfatin-1 
and escitalopram on the heat map spectra of wake, REM and non-REM sleep stages, I 
further investigated the EEG spectra in more detail using the traditional quantitative 
EEG spectral analysis (qEEG), separating AW and PW, REM sleep as well as SWS1 
and SWS2 stages. In this case, I depicted the normalized EEG power data of the 
summarized 2
nd
-3
rd
 hours in the nesfatin-1- and escitalopram-treated groups, compared 
to their appropriate (vehicle) control groups. 
On Figure 19, the EEG power spectra from 1 to10 Hz is depicted, including the 
theta (5-9 Hz) and delta (1-4 Hz) range in TW, AW and PW stages. In case of nesfatin-
1- and both doses of escitalopram-treated groups, we found a decrease in theta power 
(5-9 Hz) in TW. In the nesfatin-1-treated group, two-way repeated measure (RM) 
ANOVA showed a significant treatment × frequency interaction (F(4,10)=3.958, 
p=0.0135), while regarding the treatment effect, we found only a tendency (p=0.0535). 
The same was true for both doses of escitalopram: significant interaction effects (2 
mg/kg: F(4,80)=3.175, p=0.0179, 10 mg/kg: F(4,76)=3.390, p=0.0132;) were found. 
Interestingly, post hoc results demonstrated significant alteration at 7 Hz in the nesfatin-
1-treated group, while in the escitalopram-treated groups, at 8 Hz frequency (Figure 19, 
A and B, respectively).  
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Figure 19. Effect of nesfatin-1 and two doses (2 and 10 mg/kg) of escitalopram on 
the EEG power of total-, active- and passive wake (TW, AW and PW, respectively) 
during the 2
nd
-3
rd
 h of passive (light) phase (A-F). In TW, normalized theta power (5-
9 Hz) decreased in the nesfatin-1-treated group and in both escitalopram-treated groups 
(A and B, respectively). In AW, only the escitalopram-treated groups showed a 
reduction in theta power (D), while in PW, the theta power was diminished only in the 
nesfatin-1-treated group (E), compared to control. AW in nesfatin-1-treated group as 
well as PW in the escitalopram-treated groups did not show any alteration (C and F, 
respectively). Normalized EEG power data are presented as mean ± SEM, (2 and 10 
mg/kg escitalopram-treated groups, n=13 and 12, respectively, nesfatin-1-treated group, 
n = 6 per group). p*<0.05, p**<0.01, significant results of the Holm-Sidak’s multiple 
comparisons test.  
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In the theta power of AW, RM ANOVA showed a significant treatment effect in 
the 2 mg/kg escitalopram-treated group (F(1,20)=4.944, p=0.0379) and a treatment × 
frequency interaction only in the escitalopram-treated groups: (2 mg/kg: F(4,80)=4.356, 
p=0.0031; 10 mg/kg: F(4,76)=4.605, p=0.0022). Post hoc results were significant in both 
escitalopram-treated groups, at 8 Hz frequency (Figure 19, D). In the nesfatin-1-treated 
group, theta range showed no alteration, compared to control (Figure 19, C).  
In contrast to AW, in PW the nesfatin-1-treated group showed a decrease in 
theta power (RM ANOVA ‘treatment effect’: F(1,10)=6.994, p=0.0245), while the 
escitalopram-treated groups revealed no alteration in the theta power in PW (Figure 19, 
E and F, respectively). The post hoc comparisons showed significant result in the 
nesfatin-1-treated group at 7 Hz frequency (Figure 19, E).  
Regarding REM sleep, both nesfatin-1 and escitalopram caused a definite 
decrease in the relevant theta power. In the nesfatin-1-treated group we found a 
significant treatment × frequency interaction (F(4,32)=2.858, p=0.0393) with a significant 
post hoc result at 8 Hz frequency (Figure 20, A). Although it needs to be noted that due 
to the REM sleep-inhibiting effect of nesfatin-1, qEEG data of REM sleep were 
calculated only from data of four animals. In the 2 mg/kg escitalopram-treated group, 
we found a significant treatment × frequency interaction (F(4,80)=3.021, p=0.0225), with 
a significant post hoc result at 8 Hz frequency (Figure 20, B). However, the 10 mg/kg 
escitalopram-treated group showed a significant treatment × frequency interaction 
(F(4,64)=3.109, p=0.0211), without any significant post hoc result (Figure 20, B).  
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Figure 20. Effect of nesfatin-1 and two doses (2 and 10 mg/kg) of escitalopram on 
the EEG power of rapid eye movement (REM) sleep during the 2
nd
-3
rd
 h of passive 
(light) phase, compared to vehicle control. Normalized theta power (5-9 Hz) 
decreased in both escitalopram-treated groups (B). Notably, theta power also showed a 
reduction in the nesfatin-1-treated group, although the amount of REM sleep data was 
only n=4. Normalized EEG power data are presented as mean ± SEM, (control, 2 and 
10 mg/kg escitalopram-treated groups, n=9, n=13 and 12, respectively; control as well 
as nesfatin-1-treated group, n = 6 and 4, respectively). p*<0.05, significant results of the 
Holm-Sidak’s multiple comparisons test.  
 
Considering non-REM sleep, we did not find any spectral alteration in SWS1 
and SWS2 in the investigated nesfatin-1- and escitalopram-treated groups, compared to 
their control (Figure 21).  
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Figure 21. Effect of nesfatin-1 and two doses (2 and 10 mg/kg) of escitalopram on 
the EEG power of light- and deep slow wave sleep (SWS1 and SWS2, respectively) 
during the 2
nd
-3
rd
 h of passive (light) phase (A-D). Delta power (1-4 Hz) in SWS1 
and SWS2 showed no alteration either in the nesfatin-treated group (A and C, 
respectively) or in the escitalopram-treated groups (B and D, respectively). Normalized 
EEG power data are presented as mean ± SEM, (vehicle and 2 and 10 mg/kg 
escitalopram-treated groups, n=9, n=13 and 12, respectively, nesfatin-1-treated group 
and controls, n = 6 per group).  
 
As a short summary, beyond similarities in the effect of nesfatin-1 and 
escitalopram, namely, the alteration in theta power in REM sleep and TW, comparison 
of AW and PW data reveals differences. While nesfatin-1 decreases the theta power 
solely in PW, escitalopram affected theta power of AW, causing a deceleration in the 
theta oscillation (reduction in the peak of theta power), rather than in the total power. In 
TW and PW, both doses of escitalopram shift the peak frequency of theta power from 7 
Hz to 6 Hz, while in AW this shift was observed only in the 10 mg/kg-treated group. In 
the nesfatin-1-treated group, theta peak was unaffected.   
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9. Discussion 
This work is aimed to summarize our immunohistochemical and 
electroencephalographical findings regarding the role of two neuropeptides, the MCH 
and the nesfatin in the regulation of sleep and wakefulness.  
We found markedly increased activation in the MCH neurons as a result of 
‘REM sleep rebound’ (‘rebound’) in all the investigated hypothalamic/thalamic 
structures, such as the ZI, LH and PFA, and this activation was reduced by previous (10 
mg/kg) escitalopram treatment. The MCH/nesfatin/Fos triple-immunostaing revealed a 
strong neuronal activation of MCH/nesfatin population as a result of ‘rebound’, while 
the MCH-negative nesfatin neurons showed increased Fos positivity only in the LH, 
compared to controls. The involvement of endogenous nesfatin in sleep regulation was 
further investigated by exogenously (icv)-administered nesfatin on vigilance, 
demonstrating a mostly REM sleep-suppressing and PW-increasing effect. The 
comparison of EEG spectral effect of nesfatin and escitalopram (2 and 10 mg/kg)  
showed similarities, like reduction of theta power in TW and REM sleep, although a 
more detailed spectral analysis revealed differences between nesfatin and escitalopram. 
While nesfatin decreased theta in PW, escitalopram diminished it in AW, and shifted 
theta peak to a lower value. In the EEG spectral analysis, we also demonstrated the 
application of ‘state space analysis’, a relative new method, that provides a quick 
topographical depiction of vigilance to visualize shifts in the EEG spectral content of 
different stages of sleep-wake cycle without visual EEG scoring.  
To examine the association between the hypothalamic/thalamic neuropeptides 
and REM sleep, we used the classic ‘flower pot’ REM sleep-deprivation method to 
provoke the forced activation of neuronal populations possibly involved in the 
regulation of REM sleep. This 72 h-long procedure leads to a ca. 6-7-times increase in 
the amount of REM sleep during the 3 h-long ‘REM sleep rebound’ [36]. This type of 
REM sleep deprivation methods utilizes one of the key features of REM sleep, namely 
the absence of muscle tone. Briefly, rats are kept on single ‘small platforms’ surrounded 
by water, and when they switch to REM sleep, they fall into the water and awaken 
[168]. Besides, I mention that using ‘large pot’ kept animals (LP) as ‘stress controls’, 
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the effect of REM sleep deprivation can be differentiated from the unavoidable stress, 
since due to the larger surface of the pot, these animals are able to sleep, although they 
undergo the same stress like ‘small pot’ kept (SP) rats [157, 169, 170]. The similar 
stress-level is confirmed by the likewise elevated ACTH and corticosterone levels in the 
plasma, as well as the increased CRH in the hypothalamic PVN and the negative energy 
balance of both SP and LP animals, suggesting a similarly increased activity of the 
hypothalamic-pituitary adrenal axis [170, 171]. Despite the presence of a moderate 
SWS deprivation besides the total REM sleep deprivation on the ‘small pots’, this 
technique is considered a highly selective REM sleep deprivation method causing an 
increased amount of REM sleep, even compared to LP controls [36, 112, 156, 157, 
172].  
Based on our earlier findings, demonstrating a positive correlation between the 
neuronal (Fos) activation of the hypothalamic MCH neurons as a result of ‘rebound’, 
first, we performed a more detailed morphometrical analysis investigating the activated 
portion of the MCH neurons in different hypothalamic/thalamic nuclei. According to 
our results, ‘REM sleep rebound’ produced a markedly elevated activation of MCH 
neurons in all the investigated areas, such as the ZI, the LH and the PFA. The LH and 
the PFA have been implicated in the control of several physiological functions, 
including feeding, energy homeostasis, cardiovascular regulation, locomotor activity 
and the regulation of sleep and wakefulness [173]. However, ZI, “the zone of 
uncertainty”, is considered to be the main centre in the diencephalon for the generation 
of direct visceral, arousal, attention and posture/locomotion responses to somatic or 
visceral stimuli [174]. To date, hardly any functional studies have investigated the role 
of ZI in sleep-wake cycle [174, 175], however, more recent data in narcoleptic mice 
have demonstrated that Hcrt gene transfer into the ZI was able to suppress muscular 
paralysis [176].   
However, cell groups of ZI are contiguous and neurochemically identical with 
neuron populations of the hypothalamus, suggesting a close structural and functional 
connection between ZI and hypothalamus [174]. The ZI has been shown to possess only 
18% of MCH neurons [177], however, this small MCH neuron population revealed a 
considerable activation as a result of REM sleep rebound in our study. This high level 
of activation during ‘rebound’ and the fact that 43% of neurons recorded from the ZI 
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were most active during REM sleep [178], suggests the functional role of ZI in the 
regulation of REM sleep. Regarding the PFH, 35% of neurons recorded from this 
structure showed their maximal firing rate during REM sleep suggesting the impact of 
also this area in the regulation of REM sleep [178]. Koyama et al. also recorded neurons 
from these areas that showed activity during both REM sleep and wake (ZI and PLH: 
23% and 12.3% of all the investigated neurons, respectively), while during SWS, only 
10% or less of neurons showed maximal firing rates in these areas. The role of PFH and 
ZI is notable especially in the regulation of phasic events, rather than the maintenance 
of REM sleep, moreover, these areas are considered to be involved also in the 
maintenance wake. However, ZI seems to be more closely involved in the induction of 
REM sleep and the generation of phasic motor or autonomic events during this stage, 
than PFH, namely, rapid eye movements, respiratory irregularities and blood pressure 
fluctuations [178]. Taken together, the high-level activity of MCH cells during ‘REM 
sleep rebound’, in line with earlier findings, further supports the strong relationship 
between REM sleep and the MCH system, moreover, suggests the involvement of ZI, 
PFA and LH in the regulation of REM sleep.  
The therapeutic effect of escitalopram, the SSRI antidepressant, is linked to its 
extracellular serotonin level-increasing effect as a result of 5-HT reuptake inhibition. 
Since neuronal pathways and receptors involved in the therapeutic effect of SSRIs are 
largely overlapped with those in sleep regulation, these medications influence sleep, 
however, escitalopram is considered to be the less disruptive to sleep architecture 
among SSRIs [35, 179]. Yet, with increasing the serotonergic tone, escitalopram 
reduces the time spent in REM sleep in humans and rodents as well [35, 180]. This 
REM sleep-suppressing effect has been shown to prevail even in ‘small pot-deprived’ 
animals, when the ca.6-7-fold increased amount of REM sleep reduced by half [36]. In 
accordance with this, we observed a decrease in the activation of the MCH neurons 
following the 3 h ‘REM sleep rebound’ in all the investigated structures, despite the fact 
that Fos-positivity of MCH neurons was well above the physiological level. This 
decrease in the Fos-positivity of the MCH neurons can be the attributable to a direct 
postsynaptic inhibition effect of 5-HT [100] caused by the increased serotonergic tone 
evoked by escitalopram. In contrast to these in vitro findings, Kumar et al. have found 
increased Fos-IR in MCH neurons as a result of 5-HT given locally by unilateral 
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perfusion into the PF-LHA, possibly due to the reduction of inhibitory influences of 
GABAergic neurons by 5-HT [181]. Another possible explanation for the decrease of 
Fos-positivity of MCH neurons and REM-suppression can be the inhibition of the 
cholinergic neurons in the LDT/PPT, a core structure in the promotion of REM sleep. 
This inhibition is probably mediated through 5HT1A receptors, as in 5HT1A receptor 
knockout mice, the REM sleep-suppressing effect of citalopram has not been detected 
[34], moreover, the selective 5HT1A receptor agonist ipsapirone is a strong REM sleep-
suppressor in human [182]. However, MCH neurons have projections, among others, 
toward the LDT/PPT and the DRN [111], raising the possibility of a bidirectional 
interaction among the two systems. 
 On the other hand, escitalopram treatment was not able to diminish the 
activation of MCH neurons in the control (HC-SSRI) group, despite its definite REM-
suppression detected in these rats [36]. It can be interpreted (i) by a floor-effect, as 
MCH/Fos was below 1-2% in the HC-SSRI group. On the other hand, (ii) although 
MCH neurons have primarily been involved in REM sleep generation, their function has 
also been suggested in the regulation of non-REM sleep, which stage was not inhibited 
by escitalopram, and other physiological functions as well, such as feeding [112, 113] 
[111].  
The remarkable association between REM sleep and MCH directed our attention 
to nesfatin, the neuropeptide that is co-expressed by all MCH-containing neurons in the 
hypothalamus and ZI [128]. To investigate the nesfatin- and MCH-positive neuron 
populations at the same time, we performed MCH/nesfatin/Fos triple immunostaining. 
The MCH-nesfatin co-expression rate was the highest in the ZI, lower in the LH and the 
lowest in the PFA, similarly to literature data [128]. The ‘REM sleep rebound’ evoked a 
strong Fos expression in large percent of MCH-positive nesfatin neurons in all the 
investigated areas, like ZI, LH and PFA. However, MCH-negative nesfatin cells showed 
a moderate but significant increase in activation only in the LH, compared to controls, 
suggesting that nesfatin-IR cells exclusively in the LH can be associated with regulation 
of REM sleep, while other populations of MCH-negative nesfatin cells are possibly 
under a different regulation. However, the highly increased activation of MCH/nesfatin 
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co-expressing neurons suggests a strong association with REM sleep of all the 
investigated areas.  
The association between nesfatin expression and REM sleep regulation is 
strengthened by our in situ hybridization and ELISA findings showing a decreased 
nesfatin expression a result of REM sleep deprivation, while during ‘REM sleep 
rebound’ these expressions returned to the control levels  [171]. In line with these data, 
Jego et al. have found a positive correlation between the (Fos) activation of nesfatin 
neurons and the amount of REM sleep quantities, although they applied a shorter (6 h) 
REM sleep-deprivation and a shorter (2 h) rebound time [183].  
Considering that nesfatin has been shown to influence food intake as an 
anorexigen [134], it is crucial to clarify that despite negative energy balance during the 
REM sleep-deprivation, the cumulative food intake was not changed significantly, 
compared to HC and LP controls [171].  
To further examine the suggested link between endogenous nesfatin-expression 
and REM sleep, we examined the effect of exogenously (icv)-administered nesfatin-1 
on the architecture of sleep-wake cycle and the quantitative EEG spectra of different 
vigilance stages. The applied 25 pmol dose of nesfatin-1 was established based on 
previous studies [81, 134, 139]. As icv procedure - despite the former habituation - is 
usually accompanied by increased plasma ACTH and corticosterone levels in the first 
30 and 60 min, respectively [139, 143], we omitted the first hour and evaluated EEG 
data from the beginning of the 2
nd
 to the end of the 6
th
 hours (as part of passive phase), 
as well as the 13
th
-18
th
 hours (as part of active phase) to investigate the possible 
prolonged or rebound effect. The most striking influence of icv nesfatin-1 on the pattern 
of sleep-wake cycle was the IS- and REM sleep-decreasing effect that lasted 5–6 hours 
following administration. Decrease in both the number and the average duration of 
REM sleep and IS episodes seemed to be implicated in this effect, suggesting that 
neurons responsible for the induction and maintenance of IS and REM sleep may be 
influenced. We also showed a remarkable alteration in PW: the increase in this stage 
was still significant in the 6
th
 hour, although AW revealed no alteration in any hour. 
However, sleep fragmentation (the number of awakenings) also increased significantly. 
The decline of REM sleep and IS was probably associated with a short-time increase of 
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SWS1 in the 3
rd
 and 4
th
 hours, however, the amount of SWS2 was unaffected. The total 
sleep time showed only a tendency for decrease. Regarding active (dark) phase, we did 
not find any prolonged or rebound effect of icv nesfatin-1.  
The precise mechanism of action regarding the effect of nesfatin in the sleep-
wake regulation needs a refinement in the future. Enhanced activity of different 
component of the ARAS, like the serotonergic, noradrenergic, and/or reduction in the 
arousal threshold of the midbrain reticular formation by nesfatin-1 directly or indirectly, 
could be one explanation. This hypothesis is in line with the results of Yoshida et al., 
namely that icv injected nesfatin-1 induced neuronal activity (Fos expression) in 
serotonergic cells of the DRN and MRN as well as in the noradrenergic neurons in the 
LC [143], structures comprising parts of the ARAS, subsequently enhancing the 
activation of vlPAG and the adjacent lateral pontine tegmentum. These latter regions are 
expected to function as REM-off structures giving inhibitory GABAergic innervation to 
the SLD, that possesses REM-on function [14, 184]. However, icv nesfatin-1 injection 
also caused (Fos) activation of neurons in the PVN, the nucleus of the solitary tract and 
the SON [143]. As these structures have been related to stress, their activation 
consequently may alter sleep architecture too [185-187]. Increase in the time spent in 
PW by nesfatin, similarly to escitalopram, suggests an increased serotonergic tone, as in 
contrast to other wake-related neuromodulatory systems, serotonergic neurons support a 
state of quiet or relaxed wakefulness [188].  
However, beyond the similarities in the effect of nesfatin-1 and the serotonergic-
tone increasing escitalopram, like reducing the amount of REM sleep, decreasing the 
number and average duration of REM episodes as well as increasing PW and SWS1 
amount, there are also differences, namely, while nesfatin decreases IS amount and 
episode numbers, escitalopram caused an increase in this stage [180].  
The IS sleep stage, that usually precedes or follows REM sleep, is characterized 
by high-amplitude anterior cortex spindles as well as low-frequency hippocampal theta 
oscillation. This stage is suggested to correspond to a brief functional disconnection of 
the forebrain and the brainstem as a result of the massive decrease of brainstem 
ascending influences [15]. The mental content of IS, namely “feeling of indefinable 
discomfort, anxious perplexity and harrowing worry” was reported in normal subjects 
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when behaviourally awakened from this stage. This mental content was presumably 
linked to the transient suppression of the brainstem ascending influences, leading to 
uncontrolled higher nervous processes. The discrepancy in the IS effect of nesfatin and 
escitalopram may be explained by their different effect on the ascending brainstem 
influences, or on the GABAergic influences, leading to hyperpolarisation of 
thalamocortical neurons, the degree of which is very high during IS. However, literature 
data regarding the neuroanatomical regulation of IS are very sparse [15].  
Thus, despite the considerable overlap between the influence of nesfatin and 
escitalopram, we cannot explain the effect of icv nesfatin-1 on vigilance with an 
increased serotonergic tone exclusively. To clarify the mechanism how nesfatin 
influences sleep-wake cycle, and to prove the involvement of a serotonergic component 
in the effect of nesfatin, further studies are needed.   
In contrast to our results, Jego et al. have reported REM sleep-increasing effect 
of icv nesfatin-1, but this effect was significant only when injecting 250 pmol dose, and 
when cumulating REM sleep quantities over the 8h post-treatment. They did not detect 
any change in the average duration of REM sleep episodes, non-REM sleep and 
wakefulness [114]. (i) One feasible explanation for this discrepancy is that Jego et al. 
have examined the effect of icv nesfatin-1 in active phase, when rats spend most of their 
time with activity, and accordingly, the global state of the brain is different from that in 
the passive phase, when rats mostly sleep. (ii) Another cause of the difference can be 
that they applied a 10-times higher dose of nesfatin-1 than us. It is possible that the 
effect of icv nesfatin-1 on vigilance shows a biphasic U- or J-shaped dose-response 
curve, a widely observed phenomena, where inhibition can be seen only when the agent 
is present in low concentration, while at higher concentrations, the inhibitory effect is 
lost and a stimulatory effect can be observed [189]. (iii) Another interesting point to 
note is the molecular mechanism of nesfatin, namely, this neuropeptide may influence 
cross-binding of the receptor with various types of G protein, initially activating Gi, 
followed by the activation of Gs protein which could also be an explanation for this 
inverse effect in different concentrations [127].  
 In view of the relationship of nesfatin and MCH, it is interesting to note their 
opposite effect in the regulation of vigilance. Unlike nesfatin-1, MCH has been 
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demonstrated to induce a dose-dependent increase of REM sleep and to a minor extent 
an elevation of SWS, when injected icv [112]. Consistently, MCHR1 antagonist 
compounds have been found to decrease REM sleep, IS and SWS2, while increased 
wakefulness [113]. According to Verret et al., MCH may promote REM sleep indirectly 
by inhibiting neurons themselves suppress the REM-executive neurons during wake and 
SWS, namely the monoaminergic neurons in the brainstem and histaminergic neurons 
of the PH [112]. However, GABAergic REM-off neurons originating from the vlPAG 
inhibit the sublaterodorsal nucleus (SLD), the structure that contains glutamatergic 
REM-executive (‘REM-on’) neurons [14, 184]. It would be logical to assume that the 
co-expressing nesfatin may act on the same neurons compensating the effect of MCH. 
Another possibility, that nesfatin modulates the amount of REM sleep via an excitatory 
action on the intermingled orexinergic neurons that are active during wakefulness, but 
silent in REM sleep. It would not be surprising given the putative somasomatic, 
axosomatic and axodendritic connection between orexin and nesfatin-containing MCH 
neurons [75].  
Moreover, on food intake and energy expenditure, the effect of MCH and 
nesfatin are also opposing [81, 106, 134]. Chronic icv infusion of MCH has been 
reported to increase body weight in mice, particularly when mice were fed with 
moderately high-fat diet [190], while continuous infusion of nesfatin to the 3
rd
 ventricle 
diminishes body mass [130]. In agreement with the sleep-promoting and energy 
conserving effect of MCH, it decreases body temperature, heart rate and metabolic rate 
by enhancing the ratio of parasympathetic/sympathetic tone [95], while centrally 
administered nesfatin-1 causes a dose-dependent elevation in temperature [134], 
increases blood pressure [191] as well as ACTH and corticosterone levels [143].  
Co-localization of MCH with other neuropeptides having opposite effect is not 
unique. A high percent of the orexigenic MCH neurons (ZI: 95%, LH: 70%) co-
localizes with the anorexigenic CART [117], that divides MCH population into two 
functionally divergent clusters: the CART-positive MCH neurons send ascending 
projections toward the septum and the hippocampus, while the CART-negative 
population sends descending projections toward the brainstem and spinal cord [118].  
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Furthermore, regarding synaptic action of MCH, it has a predominantly 
inhibitory effect at pre- and postsynaptic levels [192] and diminishes the activation of 
N-, L- and P/Q-type calcium channels [193], while nesfatin-1 has been shown to rise 
intracellular Ca
2+
 concentrations, by facilitating Ca
2+
 entry through N-, L- and P/Q-type 
voltage-activated calcium channels. The nesfatin-caused Ca
2+
 elevation was abolished 
by pertussis toxin, suggesting that nesfatin is a ligand of a metabotropic, Gi/o-coupled 
protein. Inconsistently, nesfatin has been indicated to increase the level of protein kinase 
A, which is unusual, as the effect of Gi protein would be the inhibition of adenyl 
cyclase, causing a reduction of the cAMP-concentration, and consequently the 
inhibition of protein kinase A. As an explanation for this issue, Brailiou et al. have 
suggested that nesftain-1 may influence cross-binding of the receptor with various types 
of G-proteins [127]. Since receptor(s) for nesfatin-1 has/have not been cloned yet, the 
precise mechanism of nesfatin’s action remains to be clarified. 
To further elucidate the role of nesfatin in sleep and wakefulness, we also 
investigated its effect on the quantitative EEG spectra, with other words, how it affects 
oscillations, the composition of which is characteristic in different vigilance stages. 
Spectral analysis of EEG data is a more sensitive manner of evaluation than 
conventional visual scoring of vigilance stages, providing a better resolution and unveils 
features that cannot be detected visually [7]. The EEG-power composition of different 
vigilance stages can be revealed by evaluating EEG spectrum using Fast Fourier 
transformation (FFT) [194, 195]. Although, there is no consensus about the adaptability 
of rodent to human quantitative EEG, an increasing amount of evidence suggests that 
the neuroanatomical projections and cellular basis are relatively conserved.  
Supposing a serotonergic component in the effect of nesfatin, we compared also 
the EEG spectral data of nesfatin with two doses (2 and 10 mg/kg) of escitalopram. We 
concluded to evaluate the summarized 2
nd
-3
rd
 hours of the recordings (at the beginning 
of passive phase) based on our sleep-time data, since in these two hours, the effect of 
both icv nesfatin-1 and ip escitalopram injection is maximal. For the comparison we 
used a relative new method, the ‘state space analysis technique’.  
This technique depicts global changes in the EEG spectra, providing a quick 
global overview, a topographical heat map about the architecture of sleep-wake cycle 
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without the need to score vigilance stages, thus, this technique is considered unbiased, 
i.e. free from human mistakes. Moreover, in contrast to conventional scoring, it 
describes different vigilance stages as a continuum, rather than discrete states, providing 
higher dimensional information about sleep and wakefulness and also visualizes 
transitions between stages, namely the variations in the depth of sleep as well as 
intensity of wakefulness. However, this technique is quantifiable calculating the 
‘centroids’ (that is the arithmetic mean) of clusters, thus statistical analysis can be 
performed [21, 166].  
Using the ‘state space analysis technique’, we found a significant shift to the left 
on the x axis in the centroid position of the ‘REM sleep cluster’ in both the nesfatin- and 
10 mg/kg escitalopram-treated groups. A similar shift was observed in the centroid 
position of ‘wake cluster’ in the nesfatin- and both the 2 and 10 mg/kg escitalopram-
treated groups. As x-axis position of the epochs is sensitive to the high theta (6.5-9 Hz) 
content of the EEG spectra, shift to the left of the REM sleep and wake clusters suggests 
a decrease in theta power. However, in non-REM sleep stage, we did not find any 
alteration on the heat map spectra in either the nesfatin- or the escitalopram-treated 
groups, showing that delta power, typical in non-REM sleep, was unaffected by the 
treatments, suggesting that slow wave stage, the resting part of sleep was not altered.  
To verify these similarities in the EEG effect of nesfatin and escitalopram, we 
performed ‘conventional’ EEG spectral analysis for the same interval, in more detail. 
Our data showed that both nesfatin and the two different doses of escitalopram 
decreased theta power (5-9 Hz) in TW and REM sleep, in complete agreement with the 
results of ‘state space analysis technique’. In TW, while nesfatin decreased theta at 7 
Hz, both doses of escitalopram decreased it at 8 Hz frequency. However, their effect on 
AW and PW showed differences: while nesfatin diminished theta power in PW, both 
doses of escitalopram reduced it in AW. Moreover, the 2 and 10 mg/kg escitalopram 
reduced theta peak from 7 Hz to 6 Hz in TW (and the 10 mg/kg in AW), while nesfatin 
did not caused such an alteration.  In REM sleep, nesfatin and both doses of 
escitalopram caused a decrease in theta power at 8 Hz, while deceleration of theta 
rhythm was not observed.  
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Theta EEG rhythm is linked to tasks requiring attention or memory in human, 
while in rats, theta rhythm occurs mostly during wake associated with various types of 
locomotor activity [8, 196] and in REM sleep [197]. Theta provides a temporal code for 
pyramidal/granule cell firing that facilitates synaptic plasticity, crucial for spatial 
navigation and the formation of episodic memory [198]. The generation of theta 
oscillation has been attributed mostly to the septo-hippocampal-entorhinal system and 
several subcortical nuclei, like the DRN, the ventral tegmental nucleus of Gudden and 
the anterior thalamic nuclei [6].  
Two distinct types of hippocampal theta rhythm have been reported in behaving 
animals [6]. In rats, type I theta (4–7 Hz), appears in wakefulness, beginning several 
hundred milliseconds before particular behaviours, “voluntary”, “preparatory”, 
“orienting” and “exploratory” or when animals are immobile or during repetitive acts 
such as sniffing or whiskers movements [6, 196, 199, 200], while the second type 
characterized by higher frequency (7–10 Hz) occurs mostly during REM sleep in rats 
[201] and in response to acute stressors in rats [202]. In addition, the power of theta 
oscillation has also been used as an index for anxiety, and blockade of theta rhythm is 
applied to evaluate the efficacy of anxiolytics [203]. 
In our study, theta reduction caused by icv nesfatin-1 at 7 and 8 Hz frequency in 
wake and REM sleep, respectively, was very similar to that caused by escitalopram 
treatment, suggesting that an increased serotonergic tone is involved also in the theta-
suppressing effect of nesfatin-1, similarly to its effect on the pattern of sleep-wake 
cycle. This is in agreement with the increased Fos activity of Raphe nuclei as a result of 
icv nesfatin injection, see above [143], moreover, with the finding that GABAergic 
interneurons of the medial septum – diagonal band of Broca, being crucial in the 
generation of theta rhythm, are innervated by serotonergic pathways from the MRN 
which afferents suppress the generation of hippocampal theta oscillations. These 
afferents are able to desynchronize hippocampal theta but also can modulate stress 
response [204, 205]. 
In physiological conditions, theta reduction can also be the result of an indirect 
effect if we consider the close relationship between Hcrt- and MCH-positive or -
negative nesfatin expressing neuron populations in the DLH. The role of Hcrt in theta 
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modulation is shown by the fact that antagonist at Hcrt receptors have been 
demonstrated to suppress the footshock-induced theta waves, additionally, injection of 
Hcrt 1 or 2 into the MRN significantly increases theta power [206]. It also cannot be 
excluded that nesfatin-1 has a neuromodulatory effect on MCH neurons. MCH-
containing neurons innervate medial septum strongly, suggesting their role also in the 
generation of theta during REM sleep [207]. In line with this, Jego et al. demonstrated a 
theta-increase as a result of optogenic enhancement of MCH neurons, while optogenic 
silencing decreased that [114].  
However, serotonin hyperpolarizes MCH neurons via direct postsynaptic manner 
in vitro [100], moreover, acutely administered escitalopram, increasing the serotonergic 
tone, decreases Fos expression in MCH cells [36], reinforcing the inhibiting effect of 
serotonin in REM sleep generation via the inhibition of MCH cells. 
While during REM sleep, nesfatin and both doses of escitalopram treatment led 
to a reduction in theta power similarly, we found differences in their theta-effect during 
wake. Namely, nesfatin-1 caused a theta reduction in PW, while the two doses of 
escitalopram treatments reduced theta power during AW, suggesting the involvement of 
different components in the effect of nesfatin and escitalopram. Generally, in AW, all of 
the medullary serotonergic neurons have been found to be activated during activities 
like treadmill-induced locomotion in cat, and a strong positive correlation was found 
between the speed of locomotion and neuronal activation [188]. Theta decrease in AW 
can be accomplished by the elevated serotonergic tone as a result of escitalopram, 
evoking an inhibiting effect on the LDT/PPT cholinergic neurons that are crucial in the 
generation of theta oscillation. This serotonergic input, originates mostly from the 
MRN, inhibits theta rhythm by desynchronizing hippocampal theta activity [204, 208, 
209]. On the contrary, theta decrease in PW, as a result of nesfatin, can be explained by 
an increased neuronal activation, reported after icv nesfatin administration, not only in 
Raphe nuclei, but also in other nuclei e.g. LC and PVN, suggesting a more complex 
mechanism of nesfatin, in which serotonergic system can be a component. However, we 
have to note that basal theta power after icv administered vehicle was seemingly higher 
compared to ip-injected vehicle that may be attributable to the stress and anxiety due to 
the icv procedure. This elevated basal theta level was reduced by icv administered 
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nesfatin in PW, which effect may suggest an anti-anxiety effect, since suppression of 
hippocampal theta rhythm has been concluded to be a new reliable test of anxiolytic 
drug action, whether they act as a 5HT1A agonist, a GABAA receptor agonist or a SSRI  
[203]. The link between nesfatin and anxiety as well as stress is also suggested by the 
fact, that restraint stress has been shown to induce Fos expression in nesfatin-IR 
neurons in the PVN, SON, the nucleus of the solitary tract, LC, DRN without altering 
plasma-concentration of nesfatin-1[143].  
Moreover, we also found difference in theta decrease, namely it was detected at 
7 Hz as a result of nesfatin, while at 8 Hz after both doses of escitalopram, although the 
impact of the distinct frequencies during theta range has not been clarified so far.  
Taken together, we hypothesize that nesfatin-1, as a potential novel element of 
sleep-wake regulation, may suppress REM sleep and theta rhythm generation in wake 
and REM sleep most likely via an increase of the serotonergic tone or other components 
of the ARAS, or more hypothetically by the effect of MCH and/or Hcrt neurons in the 
DLH. The MCH-positive nesfatin population in the ZI, LH and PFA showed a strong 
connection with the augmented REM sleep amount during the ‘REM sleep rebound’, 
while MCH-negative nesfatin cells revealed increased Fos activation as a result of 
‘REM sleep rebound’ only in the LH, suggesting that MCH-negative nesfatin cells are 
under a different regulation. In the EEG spectral analysis, the results of ‘state space 
analysis technique’ provided a quick global picture depicting alterations in the EEG 
spectra as a result of treatments, moreover, the results evaluated with its quantification 
were in agreement with the conventional EEG spectral analysis. As theta power is 
associated with cognitive functions, like spatial navigation, attention, memory 
formation and synaptic plasticity, decrease in theta power as a result of nesfatin can 
deteriorate these cognitive functions. On the other hand, theta decreasing property of 
nesfatin, considered an important aspect in the effect of anxiolytic medications, may 
promote its potential use as a target to seek for antidepressant or anxiolytic medications.  
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10. Conclusions 
The markedly elevated activation of MCH/nesfatin-co-expressing neurons in the 
ZI, LH and PFA as a result of ‘REM sleep rebound’ suggests a close association 
between the regulation of REM sleep and the MCH/nesfatin-neuronal populations of 
these structures. This activation of MCH neurons was reduced by escitalopram, the 
selective serotonin reuptake inhibitor antidepressant, in the ZI, LH and PFA, suggesting 
a direct or indirect inhibitory effect of serotonin on these neurons, in line with the REM 
sleep suppressing effect of escitalopram. While MCH-positive nesfatin neurons show 
strong connection with REM sleep regulation as a result of ‘REM sleep rebound’ in the 
ZI, PFA and LH, the MCH-negative nesfatin neurons can be associated with REM sleep 
exclusively in the LH, suggesting that MCH-negative nesfatin neurons of the ZI and 
PFA may be under a different regulation.  
Nesfatin can be a potential new element in the regulation of sleep-wake cycle. 
Possessing a mostly REM-suppressing and PW-increasing effect, without altering non-
REM sleep considerably, nesfatin alters sleep pattern similarly to several antidepressant. 
Centrally injected nesfatin reduced theta power (5-9 Hz) in passive wake and REM 
sleep, that may affect functions associated with this oscillation, like attention or 
memory formation, however, delta power in non-REM sleep, namely the resting part of 
sleep was unaffected.  
The comparison of EEG spectral effect of nesfatin and (2 and 10 mg/kg) 
escitalopram showed similarities, like reduction of theta power in TW and REM sleep, 
although a more detailed spectral analysis revealed differences, namely, while nesfatin 
decreased theta in PW, escitalopram diminished it in AW, suggesting a different 
influence on the generation of theta power, however, increase in the serotonergic tone 
can be a potential component.  
To clarify the mechanism how nesfatin influences sleep-wake cycle and EEG 
spectra, as well as to prove the involvement of a serotonergic or other components in 
the effect of nesfatin-1 further studies are needed. The REM sleep and theta power 
reducing effect of nesfatin can suggest its potential role in the pathomechanism of 
depression and anxiety.   
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11. Summary 
In this work, we investigated the role of two neuropeptides, the melanin-
concentrating hormone (MCH) and the nesfatin-1/NUCB2 (nesfatin) in the regulation of 
vigilance, using neuromorphology and electrophysiology. Though the role of MCH in 
the regulation of sleep is known, the involvement of nesfatin, the co-expressing 
neuropeptide, and their expression in different hypothalamic/thalamic nuclei has not 
been examined until the start of this work. To study the link between these 
neuropeptides and sleep, we used ‘flower pot’ REM sleep-deprivation method to 
provoke the REM sleep-associated activation of neuron populations during the 3 h 
‘REM sleep rebound’ (‘rebound’). The activation of MCH- and nesfatin-positive 
neurons was investigated using double and triple immunostainings. To examine the 
influence of the serotonergic system on this activation, escitalopram, a serotonergic-
tone-increasing antidepressant was injected prior to ‘rebound’ [36]. The effect of 
nesfatin on both vigilance and EEG spectra was investigated by the 
intracerebroventricular administration (icv) of the peptide [171]. Supposing a 
serotonergic component in the effect of nesfatin, we compared the EEG spectra of 
nesfatin and escitalopram, using ‘state space analysis’ visualizing shifts in the 
topography of the main vigilance stages on heat maps. To verify these results, we 
performed also ‘conventional’ EEG spectral analysis in more detail [180]. 
The most important results: (1) ‘rebound’ activated the MCH/nesfatin neuron 
population in the zona incerta (ZI), lateral hypothalamic area (LH) and perifornical area 
(PFA) and (2) this activation was reduced by increased serotonergic tone, however, (3) 
the MCH-negative nesfatin-population was activated only in the LH. (4) Icv nesfatin 
decreased REM-sleep, increased passive wake, and (5) reduced theta power in total 
wake and REM, similarly to escitalopram, although (6) nesfatin and escitalopram 
diminished theta power differently in active and passive wake.  
Our results suggest a link between REM sleep and MCH/nesfatin-neuronal 
populations of the ZI, LH and PFA, as well as the involvement of nesfatin in the 
regulation of both vigilance and theta oscillation in REM sleep and wakefulness, 
possessing a presumed serotonergic component in this effect.  
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12. Összefoglalás 
Munkám során két neuropeptid, a melanin-koncentráló hormon (MCH) és a 
nesfatin-1/NUCB2 (nesfatin) alvás-ébrenlét szabályozásában betöltött szerepét 
vizsgáltam neuromorfológiai és elektrofiziológiai módszerekkel. Az MCH 
alvásszabályozásában foglalt jelentősége ma már tény, míg a vele ko-expresszálódó 
nesfatin szerepét, valamint különböző hypothalamicus/thalamicus magvakban történő 
expressziójukat kísérleteink megkezdéséig még nem vizsgálták. E neuropeptidek 
alvásszabályozásban betöltött szerepének tanulmányozására a ’virágcserép’ REM 
alvásmegvonás módszerrel 3 órás ’REM alvás visszacsapást’ (’rebound’) idéztünk elő, 
mellyel a REM alvással összefüggést mutató neuron populációk fokozott aktivációját 
váltottuk ki. Ezt kettős és hármas immunfestéssel vizsgáltuk. A ’rebound’-által 
megnövelt neuronális aktiváció és a szerotonerg rendszer kapcsolatát előzetes 
escitalopram (szerotonerg-tónust növelő antidepresszáns) kezeléssel vizsgáltuk [36]. A 
nesfatin alvásmintázatra és EEG spektrumra kifejtett hatását a neuropeptid agykamrába 
történő (icv) injektálásával vizsgáltuk [171]. A nesfatin hatásában szerotonerg 
komponenst feltételezve, a nesfatin és escitalopram EEG spektrumát egy hőtérkép-
elemzésen alapuló módszerrel hasonlítottuk össze, mely a főbb vigilancia-állapotok 
topográfiájában bekövetkezett eltolódásokat teszi szemléletessé. Az így kapott 
eredmények igazolására elvégeztük a ’konvencionális’, részletesebb EEG 
spektrumanalízist is [180]. A legfontosabb eredmények: (1) a ‘rebound’ az 
MCH/nesfatin neuron populáció aktivációját váltotta ki a zona incerta (ZI), a laterális 
hypothalamicus area (LH) és a perifornicalis area (PFA) területén, (2) mely aktivációt 
emelkedett szerotonerg tónus csökkentette, míg (3) az MCH-negatív nesfatin-populáció 
csupán a LH területén aktiválódott. (4) Icv nesfatin a REM alvást csökkentette, a 
passzív ébrenlétet növelte, valamint (5) a téta EEG teljesítményt ébrenlétben és REM-
ben csökkentette, az escitalopramhoz hasonlóan, noha (6) a nesfatin és az escitalopram 
aktív és passzív ébrenlétben különbségeket mutatott a téta teljesítmény mérséklésében.  
Eredményeink a ZI, LH és PFA MCH/nesfatin neuron populációinak REM 
alvással való összefüggését valószínűsítik, valamint a nesfatin alvás-ébrenléti ciklus és 
EEG oszcillációk szabályozásában betöltött szerepét mutatják REM-ben és ébrenlétben, 
a hatásban szerotonerg komponenst valószínűsítve. 
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